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Abstract
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the two major 
neurodegenerative diseases. There is a significant clinical and neuropathological overlap 
between PD and AD. A selective degeneration o f pigmented dopaminergic neurons on 
the substantia nigra occurs in PD, while neurofibrilary tangles, senile plaques and loss of 
populations of neurons are the three hallmarks of AD.
Based on the in vitro study of catecholamine neurotransmitters, it was 
hypothesized that the chronic exposure to environmental toxicants or other factors could 
trigger the aberrant oxidation of neurotransmitters like dopamine (DA) and 
norepinephrine (NE). The oxidative intermediate o-quinone would be attacked by 
glutathione (GSH), a common antioxidant in the tissue, to form a series of glutathionyl 
conjugates. The latter may be hydrolyzed by peptidase enzymes to give rise to cysteinyl 
conjugates. These metabolites are more readily oxidized than DA and NE. Therefore, 
more complicated metabolites may be formed. Preliminary study showed that some 
compounds derived from the oxidation of dopamine and norepinephrine in the presence 
of cysteine were toxic when administered in mice. These toxic metabolites may 
ultimately contribute to the neuronal degeneration.
In this study, the oxidation of NE in the presence of GSH at physiological pH was 
investigated. Under electrochemical conditions, four glutathionyl conjugates of NE were 
formed: 2-.S'-glutathionylnorepinephrine (2-J-Glu-NE), 5-5'-glutathionylnorepinephrine 
(5-5-Glu-NE), 2,5-bis-5'-glutathionylnorepinephrine (2,5-bis-5'-Glu-NE), and 2,5,6-tris-iS'- 
glutathionylnorepinephrine (2,5,6-tris-5-Glu-NE). These reaction products were isolated 
by preparative HPLC methods and structurally identified by spectroscopic methods.
XIX
including NMR, MS, and UV-Vis. Other oxidation conditions investigated include 
autoxidation, hydroxyl radical (HO»)-mediated and superoxide anion radical (Og*)-
mediated oxidation of NE in the presence of glutathione at physiological pH.
The in vitro and in vivo hydrolyses of S-iî-Glu-NE were investigated in rat brain 
homogenates and by intracerebroventricular (icv) administration in rat brains. Under in 
vitro conditions, 5-&Glu-NE was hydrolyzed to give rise to 5-&cysteinylnorepinephrine 
(5-5"-Cys-NE). Under in vivo conditions, 5-5'-Cys-NE was further metabolized into 5-S-N- 
acetylcysteinylnorepinephrine (5-5-NAc-Cys-NE).
The effects of the icv administration of 5-5-Glu-NE on the neurotransmitter levels 
of serotonergic system, dopaminergic system and noradrenergic system were 
investigated. The levels of 5-HT and 5-HIAA were increased in all brain areas studied 30 
min or 120 min after the icv administration of 5-.J-Glu-NE. The levels of NE were 
increased in midbrain (30 min) and striatum (120 min) after the icv administration of 5-5- 
Glu-NE. The levels of DA were decreased at hippocampus (120 min) and increased at 
cortex (120 min) after the icv administration of 5-5-Glu-NE. The level of HVA, a 
metabolite of DA, was decreased at midbrain 120 min after the icv administration of 5-5- 
Glu-NE.
The in vitro hydrolyses of 5-5-glutationyldopamine (5-5-Glu-DA) and 2,5-bis-5- 
glutathionyldopamine (2,5-bis-5-Glu-DA) were investigated in rat brain homogenates. 
The in vivo hydrolysis of 5-5-Glu-DA in rat brains was studied by the icv administration 
of 5-5-Glu-DA, 5-5-cysteinyldopamine (5-5-Cys-DA) and 5-5-cysteinylglycinyl- 
dopamine (5-5-Cys-Gly-DA). Under in vitro condition, 5-5-Glu-DA and 2,5-bis-5-Glu- 
DA were hydrolyzed to their corresponding cysteinyl conjugates of DA. Under in vivo
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condition, 5-5^Glu-DA was metabolized to S-i'-Cys-DA, and further metabolized into 5- 
5'-A'^acetyicysteinyIdopamine (5-5-NAc-Cys-DA). 5-5'-NAc-Cys-DA was formed after 
the icv administration of 5-&Cys-DA. S-i'-Glu-DA, 5-5’-Cys-DA and 5-.î-NAc-Cys-DA 
were observed after the icv administration of S-^-Cys-GIy-D A.
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Chapter 1 Introduction 
1.1 Neurodegenerative Diseases
Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the two major neuro­
degenerative diseases. There is a significant clinical and neuropathological overlap 
between PD and AD. Therefore, there might be similar but yet unknown etiological 
factors in PD and AD\
PD is an idiopathic, chronic neurologic disorder. PD was first described by an 
English physician named James Parkinson in 1817 .^ Although almost 180 years have 
passed, the cause or causes of PD still remain unknown. PD afflicts approximately 10% of 
people over the age of 65 ,^ while another study showed an annual incidence of 15- 
20/100,000“*. PD is clinically defined as a progressive neuronal disorder with characteristic 
symptoms of tremor, rigidity, and bradykinesia. Pathologically, PD can be defined as the 
selective degeneration of pigmented dopaminergic neurons in the substantia nigra (SN) 
with the presence of Lewy bodies*. The distribution of dopaminergic cell loss is different 
between PD and normal aging. The ventral tier of the SN pars compacta is affected most 
in PD, while the primary neuronal cell loss affects the dorsal tier of SN in normal aging*’’. 
Other neuronal systems affected in PD include the noradrenergic locus ceruleus (LC), the 
serotonergic raphe nucleus (RN), and the cholinergic nucleus basalis of Meynert (NBM)®. 
The SN supplies DA to the striatum and DA is needed for normal motor function. When 
DA is depleted in the striatum, the result is disastrous.
AD is the other major neurodegenerative brain disorder. It was first described by a 
German physician named Alois Alzheimer in 1907®. It has an insidious onset and an 
inexorable progression. Like PD, the etiopathogenesis of AD remains unknown. By an 
arbitrary dividing line of age of 65, the disease is termed as Alzheimer’s disease if it begins 
before 65 or dementia of the Alzheimer type (DAT) if after 65. DAT affects about 5-11%
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of the population over the age of 65 and as much as 47% of population over the age of 
8S‘“. It is the fourth major cause of death after heart attack, cancer and stroke in 
developed countries". Symptoms include loss of memory, impaired thought processes, 
and abnormal behavior. Eventually, patients become profoundly demented and bedridden, 
and frequently die of the intercurrent infection.
Pathological characteristics of AD include neurofibrillary tangles (NFTs), senile 
plaques (SPs), and loss of populations of nerve cells. SPs are the principal histological 
hallmark of AD and are located within the cortex, amygdala, and hippocampus. 
Noticeably, SPs frequently appear to be associated with blood capillaries'^. SPs consist of 
a central core of radiating deposition of extracellular aggregates of the D-amyloid peptide 
(GAP), a 39-43 amino acid peptide, surrounded by dystrophic neurites (axons and synaptic 
terminals) with non-neuronal reactive microglia and astrocytes.
NFTs consist of paired helical filaments (PHFs)", ubiquitin and amyloid protein; 
and are found inside the cell bodies of dying neurons in certain areas of the temporal 
cortex, hippocampus and amygdala'"*, as well as in four subcortical groups of cell bodies: 
the cholinergic NBM, the noradrenergic LC, the serotonergic RN'® and the dopaminergic 
ventral tegmentum (VT)'^. PHFs are composed of highly phosphorylated forms of the 
microtubule-associated protein tau. The noradrenergic neurons in the rostral LC are 
degenerated in patients with AD'’ '*. This LC neuronal loss leads to norepinephrine (NE) 
deficiency and contributes to the depressive symptoms in AD The concentration of 
choline acetyltransferase is decreased in hippocampus and neocortex'®. Cholinergic 
neurons originating in NBM are degenerated. Degeneration of cholinergic neurons and 
concomitant impairment of cortical and hippocampal neurotransmission may lead to 
cognitive and memory deficits^ ®.
1.2. Hypotheses
1.2.1 Genetic factors
Molecular genetics can provide information on the biochemical basis of diseases 
and eventually lead to therapies for their cure and/or prevention. It is the primary aim in 
molecular genetics to identify the genes that are responsible for or contribute to the 
expression of diseases. Once such a gene is identified, its normal and/or abnormal 
functions can be studied and effective therapies may be developed.
Genetic causes are considered in both PD and AD. Lewy bodies are found in a 
great majority of PD patients by postmortem examination. The analysis of familial PD 
cases has provided information on the inheritance patterns of PD, phenotypic 
heterogeneity of familial parkinsonism. A systematic genomic search has begun but there 
are no positive results so far^ V
In contrast to the genetic study of PD, four genes that enhance BAP production or 
deposition (or both) have been associated with familial AD^ .^ It is known that all 
individuals with Down’s syndrome, for which trisomy of chromosome 21 is 
responsible^’^ '*, eventually develop AD in middle age. GAP accumulation in cerebral 
cortex in patients with AD or Down’s is an early and invariant event years or decades 
before other brain lesions and clinical symptoms. Two forms of GAP are deposited in the 
brain in AD: a 40-amino acid peptide (AG40) and a 42-amino acid peptide (GA42). Although 
AG40 accounts 90% of all GAP released from nerve cells, it is GA42 that sets the stage for 
amyloid deposition^. GAPs are clipped from G-amyloid precursor protein (GAPP) by 
enzymes dubbed G-secretase and y-secretase. GAPP is encoded in chromosome 21 and its 
mutations cause the increase of GAP secretion, particularly GA42 *^*’^ ’. Therefore, AD is 
caused by GAPP mutations through enhanced generation of GAP and amyloidogenesis.
Recently, apolipoprotein E (ApoE) in cerebrospinal fluid (CSF) has been found to
bind to BAP with high affinity^. The s4 allele of Apo-E (APOE-84) is associated with 
sporadic and late-onset familial forms of AD” . The APOE gene has three common alleles, 
s2, 83, and e4, and is located on chromosome 19^ ®. Apo-E is expressed in different tissues 
including brain and functions in lipid transport. The overexpressed ApoE4 isoform of 
ApoE binds more readily to GAP and might make GAP insoluble and prone to deposition^*.
The third and fourth familial AD genes are presenilin (PS) 1 and 2 discovered on 
chromosomes 14 and 1, respectively^^^. The production of 6 A42 is increased in plasma 
and in the media from cultured skin fibroblasts in Alzheimer’s patients who inherited 
mutant PS 1 or PS 2  genes^ '*. The increased levels of B A 4 2  were observed in brains of 
transgenic mice expressing human PS 1^ ^®.
Direct neurotoxicity of GAP can injure local neurons and their processes, causing 
profound metabolic changes — likely including PHF formation through altered protein tau 
phosphorylation in some plaque-associated neurites. GAP accumulation may cause 
oxidative injury from free radical formation as well.
1.2.2. Environmental factors
Genetic studies can provide only limited information on neurodegenerative 
diseases at the present time. Environmental factors are considered to be responsible for 
triggering the diseases by themselves or to act synergistically with the patient 
genotypes^’"^ *.
There might be a link between the incidence of PD and industrialization. A PD 
study in China indicated a higher incidence of PD in the urban industrialized areas than in 
rural regions^®. There seems to be a lower incidence of PD in recently industrialized 
countries than in those with a longer industrialization history**®. However, a study in the U. 
S. A. showed no significant increase of incidence of PD over the period of 1955-1979^*.
l-Methyl-4-phenyI-l,2,3,6-tetrahydropyridine (MPTP) was found as a toxic 
contaminant of illicit meperidine synthesis'****^ . People who injected MPTP-contaminated 
drugs developed severe parkinsonism with selective degeneration in the SN**'***. MPTP is 
taken up into cerebral astrocytes where it is oxidized to l-methyl-4-phenylpyridinium ion 
(MPP^**  ^ by monoamine oxidase-B (MAO-B)**. MPP"^  is actively taken up into 
dopaminergic nerve terminals through the dopamine transporter leading to a marked 
concentration within dopaminergic neurons**’***. Dopamine transporters are expressed 
only in dopamingergic neurons and therefore the concentration of MPP^ occurs only in 
dopaminergic neurons. Within nigral neurons, MPP^ is further concentrated in 
mitochondria. MPP^ inhibits complex I of the mitochondrial respiratory chain**® and finally 
causes nigral neuronal death^"^*. However, the search for organic toxins structurally 
similar to MPTP has not yet given any conclusive results^*.
Aluminum (Al) has been found in increased concentrations in AD affected brains** 
and aluminosilicates have been found at the cores of SPs and within neurons with 
NFTs**’**. Chronic exposure to Al is a controversial possible cause of sporadic forms of 
AD**. The role of Al in AD is supported by a) toxicological studies of the learning and 
memory of animals, b) increased incidence of the disease correlated with the exposure of 
aluminum in drinking water, and c) progress of AD is slowed down by a drug which 
selectively removes aluminum from the body. However, a conclusive case that exposure to 
Al initiates the pathological process in AD remains to be established**.
1.2.3. Oxidative stress and free radicals
The oxidative properties of oxygen play a vital role in a wide range of biological 
processes, including electron transport to produce ATP**’**. However, oxygen can also 
evoke oxidative damage by being transformed into more reactive forms, like superoxide
anion radical, hydrogen peroxide, and hydroxyl radical. These reactive oxygen species 
(ROS) can damage DNA, essential enzymes and structural proteins, and have been linked 
to neurodegenerative diseases such as PD and AD“ . Normally, the cells balance these 
oxidative events through reducing agents such as ascorbic acid (AA), glutathione (GSH), 
and a-tocopherol (vitamin E). Oxidative stress occurs when the balance between the 
production of ROS and the reducing protection ability is lost. In this situation, either ROS 
production increases or the concentrations of reducing agents and/or activities of related 
protective enzymes decrease, or both.
One source of ROS is from leakage of the respiratory chain of mitochondria where 
oxygen is ultimately reduced to water, as shown in equation 1.1:
+1e -1 +1e +1e +ie
^  +2H*^ (1.1)
During the catabolic process, catecholamines can be oxidatively deaminated by 
monoamine oxidase (MAO). MAO is a mitochondrial enzyme and is located exclusively 
on the surface of mitochondria. There are two forms of MAO, MAO-A and MAO-B. In 
the SN and striatum, for example, DA is oxidized by MAO (77% by MAO-B, 23% by 
MAO-A)*®. Hydrogen peroxide is produced when DA is oxidized by MAO, as shown in 
equation 1.2:
H O - U  S (1.2)
In the SN, when DA is autoxidized to form neuromelanin, ROS are produced, as 
shown in equations 1.3 and 1.4:
 ^  ^^  (1.3)
DA
0 " )
DA
Generally, superoxide dismutase (SOD) catalyzes the conversion of superoxide 
anion radical (d} ) into H2O2 (equation 1.5)“ . Catalase (CAT) and glutathione peroxidase 
(GSH-Px) catalyze the conversion of H2O2 into H2O. These reactions prevent the 
accumulation of free hydroxyl radicals®\ as shown in equation 1.6 and 1.7. GSH is a 
substrate of GSH-Px and is oxidized to form oxidized GSH (GSSG)(equation 1.7). GSH 
is regenerated by the action of GSH reductase (GSH-Red) coupled with reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) (equation 1.8).
.1 SOD
20j* + 2H* ------► Hj O j + O j  (1.5)
CAT
2 H2 O2  ------► O2  + 2H;0 (1.6)
GSH-Px
2GSH+H2O2 ---------► GSSG+2H2O (1.7)
GSH-Red
GSSG+ NADPH+ H* ---------- ► 2GSH + NADP* (1.8)
In the brain, the GSH system is the most important defense mechanism for 
detoxification of H2O2 into H2O. However, the GSH system is saturable, and an increased 
production of H2O2 can lead to the formation of hydroxyl free radicals with subsequent 
tissue damage®. Hydroxyl radicals may be generated through the Fenton reaction with the 
presence of trace transition metal ions, such as ferrous (Fe^"  ^ and cuprous ions (Cu^, as 
shown in equation 1.9;
H2 O2 + Fez* ------^  .OH + OH- + F03* (1.9)
Fe^  ^ is a catalyst and is regenerated by reducing agents such as AA, vitamin E, and GSH. 
Ferric ions (Fe^ "^  can also be reduced into Fe^ "^  in the presence of superoxide anion 
radicals, as shown in equation 1.10:
F e 3*+  0 }   ►  O 2 + Fez* ( l . l O )
The result of combining equation 1.9 and 1.10 is called the Haber-Weiss reaction®, as 
shown in equation 1.11:
HjOz +  ► O; + .QH + OH- (1.11)
Several lines of evidence support the oxidative stress hypothesis in PD. First, a 
high concentration of DA in nigral neurons predisposes those neurons to oxidative stress. 
When DA is oxidized by MAO, hydrogen peroxide is formed. Second, SOD activities 
appear to be increased in the SN*^ ’“ . As a result of free radicals, increased lipid 
peroxidation in the SN of PD patients was reported^. Thirdly, iron is increased in the SN 
of PD patients. Though most tissue iron exists in the form of Fe^\ Fe^  ^may be reduced to 
Fe^  ^ in the presence of neuromelanin®’. In the presence of both the Fenton
reaction (equation 1.9) and Haber-Weiss (equation 1.11) reaction may proceed to form 
hydroxyl radicals, which do the most of the damage from ROS. Finally, the level of GSH 
is reduced in PD®*’®®. As discussed earlier, people who injected MPTP-contaminated 
meperidine developed parkinsonism with selective neuronal degeneration in the SN. 
MPTP is oxidized to MPP\ which inhibits complex I of the mitochondrial respiratory 
chain and ultimately causes cell death. Excessive hydroxyl radicals produced at this 
situation can react and damage virtually any biomolecules nearby, including DNA, proteins 
and membrane lipids’®’”  and finally cause cell death. To the extent that PD is caused by 
MPTP or MPTP-like protoxins, oxidation reactions may be crucial to the development of 
PD. The MPTP model has been considered the best model of PD available.
Recently, evidence has been obtained that free radicals play an important role in 
the development of AD. A major pathological feature in the brains of AD patients is the 
presence of SPs, insoluble plaques with high-density amyloid deposits, of which GAP is a 
major component. The neurotoxicity of GAP may be related to its promotion of hydroxyl 
radical formation. GAPs can cause ROS generation and calcium homeostasis destablization 
in rat hippocampal cultures’  ^ and increased levels of H2O2 and lipid peroxides to 
accumulate in a PC 12 cell line, a clonal CNS cell line and cultured rat cortical neurons’'*. 
While the free radical production is linked to the exposure of GA25-30, a biologically active 
fragment of GAP, in rat cortical neurons’®, antioxidant drugs can prevent the calcium
elevation and cytotoxic actions of BA25.30 from PC 12 cell lines’*'. Iron is frequently a 
potent facilitator of the free radical production due to its ability to mediate the conversion 
of H2O2 to hydroxyl radicals via the Fenton reaction. It is not surprising that the iron 
increase is observed within or close to the plaques and in NFTs in AD” ’’*.
In summary, evidence supports the hypothesis that free radicals contribute to the 
pathogenesis of neurodegenerative diseases such as PD and AD.
1.3. Experimental Design
1.3.1 Hypothesis
One of the major neuropathological changes in PD is the degeneration of the 
nigrostriatal DA pathway’*’®*. This causes the depigmentation of SN and a severe 
deficiency of DA in striatum. There are some characteristic chemical and biochemical 
changes in the Parkinsonian SN. These changes include the decrease of nigral 
concentrations of GSH without an accompanying increase of GSSG concentration**’” , a 
significant increase of the of 5-5-cysteinyldopamine (5-j"-Cys-DA) to DA concentration 
ratio” , upregulation of y-glutamyl transpeptidase (y-GT), and progressive depigmentation 
of the SN*’*^ ’. In the SN, DA is autooxidized to form DA-o-quinone, and the further 
oxidation of DA-o-quinone leads to the formation of black neuromelanin (Scheme I)**.
However, DA-o-quinone possesses an electron deficient ring and is an easy target 
for nucleophilic agents. L-Cysteine and GSH are among the strongest endogenous 
nucleophiles. Indeed, experiments done in our lab show that in vitro the neuromelanin 
pathway is blocked by both cysteine and GSH**'**. When DA is oxidized at physiological 
pH in the presence of cysteine or GSH, a number of soluble cysteinyl and glutathionyl 
conjugates are formed, including S-i’-Cys-DA, 5-5-glutathionyldopamine (5-.y-Glu-DA),
2-5'-cysteinyldopamine (2-5-Cys-DA), 2-5'-glutathionyldopamine (2-5-GIu-DA), 2,5-bis-5’- 
cysteinyldopamine (2,5-bis-5-Cys-DA) and 2,5-bis-J-glutathionyldopamine (2,5-bis-5-
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Glu-DA). Based on these results, a new hypothesis has been recently advanced*’’®®. 
Basically, this hypothesis proposes that chronic exposure to environmental toxicants may 
evoke elevated biosynthesis of cysteine and GSH in glial cells and upregulation of y-GT. 
This leads to elevated translocation of GSH and/or cysteine into pigmented DA neurons 
and subsequent diversion of the neuromelanin pathway, causing the loss of GSH without 
accompanying GSSG formation, increased S-iS-Cys-DA to DA concentration ratio, and 
the depigmentation of DA neurons. Owing to the larger concentration of GSH in brain, 
GSH is postulated in vivo as the nucleophilic agent to attack the DA-o-quinone to give 
rise to glutathionyl conjugates of DA. Glutathionyl conjugates are then hydrolyzed by 
peptidase enzymes to give rise to cysteinyl conjugates of DA“ . Under conditions that DA 
is oxidized, cysteinyl conjugates of DA are even more easily oxidized than DA itself. For 
example, 5-5-Cys-DA is oxidized to give rise to a dihydrobenzothiazine (DHBT) 
compound, 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2//-l,4-benzothiazine-3-carboxyIic 
Scheme II
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acid (DHBTl) (Scheme II). Other DHBT compounds are also shown in Scheme U. At 
least one of the cysteinyl conjugates of DA and several DHBTs derived from cysteinyl 
conjugates are toxic when administered into the brains of mice and rats*®’®®.
The pigmented cell bodies of noradrenergic LC neurons degenerate in PD®^ . 
Moreover, noradrenergic neurons that project from the LC to the cortex and hippocampus 
also degenerate in AD. These neurons are degenerated in their terminal regions®^  in 
contrast to SN and LC cell bodies®^  in PD. Similar to DA, NE is easily oxidized to NE-o- 
quinone, which should be readily attacked by GSH and/or cysteine to give rise to 
glutathionyl and/or cysteinyl conjugates. The further oxidation products of glutathionyl 
and/or cysteinyl conjugates of NE may yield endotoxins which might contribute to the 
degeneration of noradrenergic neurons. It is clearly of interest to explore the influence of 
GSH on the oxidation chemistry of NE at physiological pH.
It is conceivable that DA and NE in neurons are oxidized under oxidative stress to 
form o-quinone intermediates, which are attacked by nucleophiles like GSH and/or 
cysteine. However, the level of GSH is much higher than that of cysteine. GSH is 
synthesized in glial cells and then transferred into nerve cells. It is reported that the 
concentrations of GSH are 2.41 mM in the whole brain and 3.49 mM in the striatum in 
rats®®. It is reasonable to assume that the o-quinones formed from the oxidation of DA and 
NE will first be attacked by GSH. The glutathionyl conjugates are then hydrolyzed to form 
cysteinyl conjugates via peptidase enzymes. Recently, it has been reported that a -  
methyldopamine (a-MeDA), a metabolite of the serotonergic neurotoxicants 3,4-(±)- 
(methylenedioxy)amphetamine (MDA) and 3,4-(±)-(methylenedioxy)methamphetamine 
(MDMA), is readily oxidized in the presence of GSH to form S-5-glutathionyl-a- 
methyldopamine (5-5-Glu-a-MeDA). 5-iî-Glu-a-MeDA is rapidly transformed into 5-5- 
cysteinyl-a-methyldopaime (5-5-Cys-a-MeDA) mediated by y-GT in rat brains. 5-5-Cys- 
a-MeDA is A''-acetylated to form 5-5-(/V^acetyl-5-cysteinyl)-a-MeDA (5-5-NAc-Cys-a- 
MeDA), which may contribute the long-term neurotoxicity of MDA and MDMA®®. These
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observation suggest that glutathionyl conjugates of DA and NE may also be hydrolyzed in 
reactions mediated by y-GT. Similar to the mechanism of MPTP, these cysteinyl and 
conjugates of DA and ME, in addition to their further metabolites DHBTs, might be taken 
up into the mitochondria and inhibit the respiratory chain complex I and ultimately cause 
cell death. At least one cysteinyl conjugate of DA and several DHBTs from DA and NE 
are toxic when administered in to the brains of mice and rats®’’” ’^ . This project includes 
the study of the in vitro oxidation chemistry of NE in the presence of GSH at 
physiological pH, and both the in vitro and in vivo hydrolysis of glutathionyl conjugates of 
DA and NE in rat brain homogenates and rat brains.
1.3.2. Project description
The following work was carried out:
(I) The oxidation chemistry of NE in the presence of GSH at physiological pH
A) Cyclic voltammetric methods were employed to study the reduction- 
oxidation properties of NE in the presence of GSH and of the glutathionyl 
conjugates of NE.
B) Controlled potential electrolysis was employed to electrochemically 
synthesize the oxidation products of NE in the presence of GSH. 
Preparative HPLC techniques were employed to isolate and purify the 
reaction products.
C) Spectroscopic methods, such as UV-visible spectroscopy (UV-Vis), 
nuclear magnetic resonance spectroscopy (NMR), and mass spectroscopy 
(MS), were employed to elucidate the chemical structures of glutathionyl 
conjugates of NE.
D) Autoxidation and oxygen radical-mediated oxidation of NE in the presence
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of GSH at submicromolar concentrations and physiological pH were 
studied.
(2) In vitro and in vivo metabolism of glutathionyl conjugates of NE
A) Cysteinyl, glutathionyl, cysteinylglycinyl and A^-acetylcysteinyl conjugates 
of NE were prepared by employing electrochemical synthesis and 
preparative HPLC techniques.
B) HPLC-EC systems were optimized to monitor the in vitro and in vivo 
metabolism of 5-5-glutathionylnorepinephrine (S-S'-Glu-NE).
C) In vitro metabolism of 5-5-Glu-NE in rat brain homogenates was studied at 
physiological pH. The metabolite 5-5-Cys-NE was confirmed by 
spectroscopic methods in addition to comparison of the retention time 
using HPLC methods.
D) In vivo metabolism of S-^-Glu-NE was studied by intracerebroventricular 
(icv) administration of S-i'-Glu-NE in rat brains. The effects of icv 
administration of 5-j'-Glu-NE on levels of electroactive neurotransmitters 
and their metabolites in rat brains were also studied.
(3) In vitro and in vivo metabolisms of glutathionyl conjugates of DA
A) Cysteinyl, glutathionyl, and A’-acetyl-cysteinyl conjugates of DA were 
prepared by employing electrochemical synthesis and preparative HPLC 
techniques.
B) An HPLC-EC system was optimized to monitor the 5-&Glu-DA 
metabolism.
C) In vitro metabolism of cysteinyl conjugates in rat brain homogenate was 
studied at physiological pH and 37 °C.
D) In vivo metabolism of 5-5-Glu-DA was studied by icv administration of 5- 
J-Glu-DA, 5-J-Cys-DA, and 5-5'-cysteinylglycinyl dopamine (5-5'-Cys-Gly- 
DA) into rat brains.
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Chapter 2 Oxidation Reaction of Norepinephrine in the 
Presence of Glutathione
2.1 Introduction
In the LC, noradrenergic pigmented cell bodies neurons degenerate in patients with 
PD. The pigmentation of these neurons is due to the autoxidation of NE to NE-o-quinone 
that polymerizes to neuromelanin. Noradrenergic neurons that project from the LC to the 
cortex and hippocampus also degenerate in their terminal regions in patients with AD.
Similar to DA, NE can easily be oxidized under physiological conditions. Oxidative 
stress can produce excessive ROS, which may oxidize NE to NE-o-quinone. It is 
reasonable to assume that the oxidation intermediate, NE-o-quinone, may be attacked by 
nucleophiles in the neurons such as GSH and cysteine. Since the concentration of GSH is 
much larger than that of cysteine in the cells, GSH would attack NE-o-quinone to form 
glutathionyl conjugates. The resulting glutathionyl conjugates, in turn, may be hydrolyzed 
to cysteinyl conjugates by peptidase enzymes. The oxidation of NE in the presence of 
cysteine was studied in this laboratory recently®’. Cysteinyl conjugates were formed by the 
electrochemical oxidation of NE in the presence of cysteine at physiological pH. These 
cysteinyl conjugates have more negative redox potential than NE and thus are easily 
oxidized to give rise to further oxidation products. Two products caused animal 
behavioral responses and were found lethal when administered into the brains of 
laboratory mice. The current study focused on the oxidation chemistry of NE in the 
presence of GSH at physiological pH by means of electrooxidation, autoxidation and 
hydroxyl radical oxidation.
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2.2 Experimental
2.2.1 Chemicals
Norepinephrine hydrochloride (NE»HC1), glutathione (GSH, reduced form, free 
base), A'rn-methyl-5-hydoxytryptamine (N-MET), trifluoroacetic acid (TFA), 
NazEDTA'ZHzO, and sodium ascorbate (AA) were obtained from Sigma (St. Louis, MO). 
Ammonium hydroxide, sodium phosphate (monobasic), sodium phosphate (dibasic), 
acetonitrile (MeCN, HPLC grade) were obtained from Fisher Scientific Company 
(Springfield, NJ). Hydrogen peroxide (H2O2) and ferrous ammonium sulfate 
[Fe(NH4)2*6H20] were obtained from Mallinckrodt (Paris, KY). All chemicals were used 
without further purification. All solutions were prepared with deionized water obtained 
from a Milli-Q system (Continental Water System, El Paso, TX). Phosphate buffer 
solution (PBS) of p = l.O and pH = 7.4 were prepared according to Christian and 
Purdy®*. All reaction solutions were filtered through a membrane (type HA, pore size 
0.45 nm, Millipore Corporation, Bedford, MA) before the injection into an HPLC system.
2.2.2 Instrumentation
Cyclic voltammograms were obtained at a pyrolytic graphite electrode (POE; 
Pfizer Minerals, Pigments and Metals Division, Easton, PA) having an approximate 
surface area of 12 mm\ using a BAS model 100A electrochemical analyzer (Bioanalytical 
Systems, West Lafayette, IN). The PGE was resurfaced before recording each 
voltammogram as described” . All voltammograms were corrected for iR drop. Controlled
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potential electrolyses employed a Princeton Applied Research Corporation (Princeton, NJ) 
model 173 potentiostat. The working electrode consisted of several plates of pyrolytic 
graphite having a total surface area of ca. 150 cm .^ These electrodes were suspended into 
the solution containing the appropriate supporting electrolyte and compound of interest 
contained in the working electrode compartment of the electrochemical cell. A 
conventional three-compartment electrochemical cell was employed in which the three 
compartments were separated with Nafion* membranes (Type 117, DuPont Co., 
Wilmington, DE). The working electrode compartment had a capacity of 50 mL. The 
counter electrode employed was platinum gauze. A saturated calomel electrode (SCE) 
was used as reference electrode. All controlled potential electrolyses were carried out 
with the solution into the working electrode compartment stirred with Teflon-coated 
magnetic stirring bar and nitrogen (Nz) gas bubbling vigorously through the solution. All 
potentials are referenced to the SCE at ambient temperature (22 ± 2°C).
HPLC employed a Gilson (Middleton, WÏ) binary gradient system equipped with 
two Gilson model 302 pumps, a Gilson model 112 UV detector set at 254 nm and a 
Rheodyne model 7125 loop injector with a 10 mL sample loop. Larger sample volumes 
(10-30 mL) were pumped directly onto the column through one of the HPLC pumps. A 
preparative reversed-phase column (J. T. Baker, Phillipsburg, NJ; Bakerbond CIS, 10 pm, 
25 X 2.1 cm) protected by a short guard column (Brownlee Laboratories, Santa Clara, 
CA, RP-18, 5 X 1 cm) was used. Six mobile phase solvents were used. Solvent A was 
prepared by adding 30.0 mL concentrated ammonium hydroxide to 4.0 L of deionized 
water and its pH was adjusted to 3.0 by adding TFA. Solvent B was prepared by adding
2.0 L methanol (MeOH) and 30.0 mL concentrated ammonium hydroxide to 2.0 L 
deionized water. The pH of this solution was adjusted to 2.5 by adding TFA. Solvent C 
was prepared by adjusting the pH of 4.0 L deionized water to 2.5 by adding TFA. Solvent
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D was prepared by adjusting the pH of 2.0 L deionized water and 2.0 L MeCN to 2.5 by 
adding TFA. Deionized water and MeCN were used as solvent E and F, respectively.
'H NMR (one- and two-dimensional correlated spectroscopy (COSY) 
experiments) were recorded on a Varian (Palo Alto, CA) XL-300 spectrometer. Low- and 
high resolution fast atom bombardment-mass spectrometry (FAB-MS) employed a VG 
Instruments (Manchester, U. K.) ZAB-E mass spectrometer. Ultraviolet-visible (UV-Vis) 
spectra were recorded on a Hewlett-Packard 8452 diode array spectrophotometer using 
0.5-cm pathlength quartz cuvettes.
HPLC method I was used to monitor the oxidation of NE in the presence of GSH 
and to separate and isolate the products from the reaction mixture. HPLC method I 
employed solvents A and B and the following gradient: 0-2 min, 0% solvent B; 2-7 min, 
linear gradient to 10% solvent B; 7-40 min, linear gradient to 30% B; 40-48 min, linear 
gradient to 100% solvent B; 48-55 min, 100% solvent B; 55-55.01 min, linear gradient to 
0% solvent B; 55.01-60 min, 0% solvent B. The flow rate was constant at 7.0 mL/min.
HPLC method II was used to further purify (desalting) the products obtained from 
HPLC method I. It employed solvents C and D and the following gradient profile: 0-2 
min, 0% solvent D; 2-7 min, linear gradient to 5% solvent D; 7-25 min, linear gradient to 
15% D; 25-37.5 min, linear gradient to 30% solvent D; 38-48 min, linear gradient to 
100% solvent D; 48-58 min, 100% solvent D; 58-59 min, linear gradient to 0% solvent D; 
59-65 min, 0% solvent D. The flow rate was constant at 7.0 mL/min.
HPLC method IE was used to study the oxidation of NE in the presence of GSH 
at various conditions. It was an HPLC system with electrochemical detection (HPLC-EC). 
The method employed a Bio-Rad (Hercules, CA) Model 1300 pump, a Rheodyne 7125 
injector with a 5.0 pL sample loop, and a BAS (West Lafayette, IN) LC-4C 
electrochemical detector equipped with a glass carbon detector electrode set at 800 mV
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vs. a Ag/AgCI reference electrode. The detector was set the full-scale at 10 nA. A 
reversed phase column (BAS, Phase-H ODS, 3 pm, 100x3.2 mm) was employed. The 
mobile phase consisted of 0.085% diethylamine (v/v), 0.057 mM ethylenediamine- 
tetraacetic acid (EDTA), 0.50 mM sodium octyl sulfate (SOS), and 0.10 M citric acid in 
9.3% MECN/deionized water at pH = 2.37. The flow rate was constant at 0.6 mL/min.
2.3 Electrochemical Oxidation Reaction of NE
2.3.1 Cyclic voltammetric study of the oxidation of NE in the presence of GSH
A cyclic voltammogram of NE (1.0 mM) at a PGE in pH 7.4 (p = 1.0) PBS at a 
sweep rate (v) of 200 mVs’’ is shown in Figure 2.1 A. On the initial anodic sweep, peak I, 
appears at a peak potential (Ep) of 179 mV and corresponds to the oxidation (2e, 2H ) of 
NE to NE-o-quinone (Scheme HI*” ’’®*). Following scan reversal, peak L appears at Ep of 
113 mV and corresponds to the quasi-reversible reduction of NE-o-quinone to ME.
Scheme III
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Figure 2. i Cyclic voltamograms of 1.0 mM NE al PGE in the presence of (A) 0 mM, (B) 0 .1 mM, (C) 0.4 mM, (D) 1.0 mM, (E) 5 0 mM and 
(F) 10.0 mM GSH in PBS (pH = 7.4, p = 1.0). Sweep rale; 200 mVs '.
Previous studies*®*’*®* showed that at pH 7.4, NE-o-quinone deprotonates to 7 and the 
latter cyciizes to yield 3, 5, 6-trihydroxyindoline (8). Compound 8 is then further oxidized 
(2e, llC ) by NE-o-quinone to yield the aminochrome 9 and NE. Aminochrome 9, formed 
at the surface of the electrode, is the species that is responsible for peak He (Ep = -241 
mV) on the reversal cathodic scan. Peak H, observed on the second anodic sweep appears 
at Ep = -178 mV and corresponds to the oxidation of 8 to 9. Peak Ic virtually disappears at 
v = 20 mVs * owing to the relatively rapid redox reaction between NE-o-quinone and 8.
Cyclic voltammograms (v = 200 mVs~’) of 1.0 mM NE in the presence of GSH 
(0.1 mM — 10 mM) in PBS (pH = 7.4, p = 1.0) are shown in Figure 2.1B-F. The addition 
of GSH changes the cyclic voltammetric behavior of NE. With increasing amounts of 
GSH, the peak height of reduction peak Ic and the peak H/peak Uc couple decrease. In the 
presence of 5.0 mM GSH (molar ratio of NE GSH = 1:5) peak Ic disappears. When GSH 
reaches a concentration of 10 mM (molar ratio ofNErGSH = 1:10), the peak Oa/peak He 
couple almost completely disappears. The role of GSH in the electrooxidation of NE is to 
scavenge the intermediate NE-o-quinone and thus to block the formation of 8 and 9. The 
reason that the peak Ha/peak He couple still appears might be due to the possibility that the 
glutathionyl conjugates of NE, if formed during the cyclic voltammetric process, can still 
be oxidized to give an NE-o-quinone product which undergoes a similar process to that of 
NE itself.
2.3.2 Isolation, purification and identification of oxidation reaction products
The oxidation reaction mixture was obtained by the electrooxidation of NE in the 
presence of GSH. In a typical electrooxidation reaction, NE*HC1 (4.9 mg, 24 mmol) and
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Figure 2.2 HPLC chromatogram of the product solution obtained following
controlled potential electro-oxidation of 1.0 mM NE in the presence of
5.0 mM GSH at 150 mV for 30 min in PBS (pH = 7.4, p = 0.2). HPLC 
method I. Injection volume = 2.0 mL. AUFS = 1.0.
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Figure 2.3 UV-Vis spectra of (A) 2-S-GJu-NE, (B) 5nS-Glu-NE, (C) 2,54>is-S-Glu-NE and (D) 2,5,6-tiis-S-Glu-NE as collected in mobile 
phase eluted under HPLC method II.
GSH (37 mg, 120 mmol) were dissolved in 25 mL of pH 7.4 PBS (p = 0.2). The resulting 
solution was electrolyzed at 150 mV for 30 nun under the flow of N2. Upon termination of 
the reaction the entire pale yellow solution was adjusted to pH < 3 with dilute HCl and 
filtered. Then, 10 mL aliquots of the reaction solution were repeatedly injected into the 
preparative HPLC system and the components separated using HPLC method I. A typical 
chromatogram is shown in Figure 2.2. Four major components, which were later identified 
as 2-iS'-glutathionyI norepinephrine (2-5-Glu-NE), 5-&Glu-NE, 2,5-bis-j'-glutathiony 1 
norepinephrine (2,5-bis-5-Glu-NE), and 2,5,6-tris-5-gIutathionyI norepinephrine (2,5,6- 
tris-&GIu-NE), respectively, were eluted under these conditions. Each component showed 
a unique UV-Vis spectrum in the mobile phase (Figure 2.3). These UV-Vis spectra were 
used to assist the collection of each component for verification purposes during the initial 
isolation and purification
—a —ME 
— 2 l^u-ME
-^ V-2,Wi»&Clw4IE 
— 2,S,64ri»S«lu4IE
■§) 60-
(desalting) processes.
Controlled potential 
electrooxidation of ME at the 
PGE in PBS (pH = 7.4, p = 
0.2) at 150 mV for 30 minute
GSH showed similar product 
patterns (Figure 2.4). 5-S- 
Glu-NE is the major product 
and the 2,5-bis-5'-Glu-NE is 
the second major one. The yield of 2,5,6-tris-.y-GIu-NE is the lowest. Overall, the product 
yields reached maximum at ratios of GSH:NE between 2 and 4. When the molar ratio of 
GSH'.NE was greater than 5, the relative yield of each product did not change very much.
0 2 4 6 8 1
Molar ratio of GSH:NE
Figure 2.4 Product yields vs. molar ratio of GSH:NE at 
controlled potential electrooxidation of ImM 
ME in PBS (pH = 7.4, p = 0.2) at 150 mV 
for 30 min.
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Therefore, a molar ratio of GSH:NE = 5 was chosen for the rest of the experiment. At a 
fixed GSH:NE molar ratio of 5, the relative yields of each major product are shown in 
Figure 2.5. During the first 40 min, the yield of each product grew very quickly, while 
after 60 -  90 min, the yields of each product remained relatively unchanged (except the
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« —2^lu-NE
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Figure 2.5 Time dependence of relative yields of the products formed after the controlled
potential electrooxidation of ImM NE and 5 mM GSH at PGE in PBS (pH = 7.4,
H  = 0.2) at 150 mV.
yield of 2,5-bis-5'-Glu-NE which continued to form). The electrolysis time of 60 min was 
employed in the following procedures to prepare the reaction mixture for HPLC 
separation.
The four major components were collected separately. Each component was 
immediately frozen on dry ice and subsequently fireeze-dried. The resulting white solid 
materials, which contained TFA from the HPLC mobile phase (HPLC method I), were 
dissolved in minimum volume of deionized water and purified using HPLC method II 
(desalting). Assignments of 'H NMR resonance to structures of reaction products, 2-5-
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GLu-NE, 5-5-Glu-NE, 2,5-bis-5-Glu-NE, and 2,5,6-tris-&Glu-NE, were based on the 
comparison with 'H NMR spectra of NE (Figure B. 1 in Appendix B) and GSH (Figure
B.2 and B.3 in Appendix B), and were confirmed using two-dimensional COSY NMR 
experiments. NMR data for glutathionyl conjugates dopamine®’ and cysteinyl conjugates 
of norepinephrine®’ were also used as comparison with those of the reaction products.
2>.$-glutathionylnorepinephrine (2-iS-GIu-NE)
2-5'-GLu-NE eluted at tR = 27.5 min and its UV-Vis spectrum showed bands at 
Aroax = 258 nm and 292 nm (A238/A292 = 0.88) in mobile phase at pH = 2.5. It was isolated 
as a white solid. In PBS (pH = 7.4, p = 1.0), it exhibited UV bands at A^/nm 
(log 8max/M’em"'): 256 (3.65) and 294 (3.62)
O
(Figure B.4 in Appendix B). FAB-MS (glycerol
HOOC w I
matrix) gave m/e = 475.1491 (MH, 23%, H O O C x^N >J^,
C,gH27N4Ü9S; calculated m/e = 475.1499) (Figure HOs^^sLA^NH 
B.5 in Appendix B). *H NMR (CD3OD) gave 5: 7.00
(d, J5.6 = 8.1 Hz, IH, C(5)-H), 6.87 (d, J;6 = 8.1 Hz, 2-S-Glu-NE
IH, C(6 )-H), 5.48 (dd, J5.6 = 9.7, 2.9 Hz, IH, C(a)-H), 4.51 (t, J = 6.3 Hz, IH, C(d)-H), 
3.91 (t, J = 6.5 Hz, IH, C(a)-H), 3.84 (d, J = 4.2 Hz, 2H, C(f)-H2), 3.19-3.08 (m, 2H,
C(e)-H2), 2.93-2.85 (m, 2H, C(P)-H2), 2.62-2.44 (m, 2H, C(c)-H2), 2.17-2.10 (m, 2H,
C(b)-H2) (Figure B.6  and B.7 in Appendix B). These data reveal the structure of the first 
peak, is 2-5'-glutathionylnorepinephrine (2-5-Glu-NE), C,gH26N4 0 gS, M = 474.14.
5-5-gIutathionylnorepinephrine (5-5-Glu-NE)
The second component, 5-5-Glu-NE, eluted at tR = 37 min and showed UV-Vis 
spectrum bands at Ama% = 256 nm and 292 nm (Az^ g/Azpz = 1.4) in mobile phase at pH =
26
2.5. It is a white solid compound and in PBS (pH = 7.4, p = 1.0), it exhibited UV bands at 
A^/nm (log Braa/NT' cm"'); 254 (3.77) and 294 (3.57) (Figure B.8 in Appendix B). F AS­
MS (thioglycerol/glycerol matrix) gave m/e = 475.2 (MH% 100%, C,gH27N40,S; calculated 
OH m/e = 475.1499) (Figure B.9 in Appendix B). *H NMR
J I J  (D2O) gave 5: 6.84 (d, hs  = 2.1 Hz, IH, C(2)-H), 6.74 (d,
.  S J2.6 = 2.1 Hz, IH, C(6)-H), 4.69-4.65(m, IH, C(a)-H), 4.23
H O O C^N % ^
HOOC H I
O
HO'
O S
,NH
5-S-Glu-NE
(dd, J = 4.8, 8.4 Hz, IH, C(d’)-H), 3.63 (s, 3H, C(f)-H, 
C(a’)-H), 3.84 (dd, J = 14.7, 4.8 Hz, IH, C(e')-H), 3.09-2.94 
(m, 3H, C(e')-H, C(p)-H2), 2.26 (t, J = 7.5 Hz, 2H, 
C(c’)-H2), 1.93 (m, 1.88-1.92, 2H, C(b’)-H2) (Figure B.9 and B.IO in Appendix B). These 
data reveal the structure of the second component is 5-5'-gIutathionylnorepinephrine (5-S- 
GIu-NE), C.gHzsN^OgS, M = 474.14.
2, S-Bis-.S-glutathionylnorepinephrine (2,S-bis-5-GIu-NE)
The third component, 2,5-bis-5-Glu-NE, eluted at ta = 42.5 min and showed an 
UV-Vis band at = 276 nm with a shoulder band at 305 nm (A276/A305 = 3) in mobile 
phase at pH = 2.5. It was isolated as a white solid. In PBS (pH = 7.4, p = 1.0), it exhibited 
UV bands at XmJnm (log Gm«/M"' cm''): 274 (4.17) and 310 (3.73) (Figure B.12 in
Appendix B). FAB-MS (thioglycerol/glycerol 
matrix) gave m/e = 780.2192 (MH% 95%, 
C28H42N7O15S2; calculated m/e = 780.2180)
(Figure B.13 in Appendix B). ’H NMR (D2O) gave 
Ô: 7.02 (s, IH, C(6)-H), 5.31 (dd, J = 3.0, 9.0 Hz, 
IH, C(a)-H), 4.27-4.20 (m, 2H, C(d)-H, C(d')-H), 
3.77 (m, 4H, C(f)-H, C(f)-H), 3.77-3.64 (m, 4H, 
C(f)-H2, C(f)-H2), 3.25 (dd, J = 14.4, 4.8 Hz, IH,
HOOC
HO NH2
HO
O S
i VHOOC
o
2,5-bis-S-Glu-NE
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C(e)-H), 3.14-2.73 (m, 3H, C(e')-H, C(p)-H2), 2.33-2.26 (m, 4H, C(c).H:, C(c')-Hz),
2.04-1.93 (m, 4H, C(b)-H2, C(b')-H2) (Figure B.14 and B.15 in Appendix B). These data 
reveal the structure of the third component is 2, 5-bis-5'-glutathionyl-norepinephrine (2,5- 
bis-iJ-Glu-NE), C2sH4iN7 0 i5S2, M = 779.21.
2, 5, 6-Tris-<S-glutathionylnorepinephrine (2,S,6-tris-5-Glu-N£)
The fourth component, 2,5,6-tris-5-Glu-NE, eluted at ta = 47 min and showed no 
specific UV-Vis bands but with a wide shoulder at = 320 nm in mobile phase at pH =
2.5. It was isolated as a white solid compound. In PBS (pH = 7.4, p = 1.0), it exhibited 
UV bands at L««/nm (log Emax /M~‘cm''): 266 (4.43) and 328 (3.86) (Figure B.16 in 
Appendix B). FAB-MS (Thioglycerol/ glycerol/1000 PEG matrix) gave m/e = 1085.2784 
(MH% 5.2%, C3gH57Nio02iS3; calculated m/e = 1085.2862) (Figure B.17 in Appendix B). 
'H NMR (D2O) gave 5; 6.02 (dd, J = 10.8, q
3.6 Hz, IH, C(a)-H), 4.45-4.39 (m, 2H,
C(d')-H, C(d")-H), 4.04 (dd, J = 9.0, 3.0 Hz, HOOC^
O S OH
IH, C(d)-H), 3.77 (m, 3H, C(a)-H, C(a')-H,
C(a")-H), 3.77-3.64 (m, 6H, C(f)-H2, C(f)- °
V
IH, C(e)-H), 3.14-2.73 (m, 3H, C(e')-H2, O
C(P)-H2), 2.33-2.26(m, 6H, C(c)-H2, C(c')- 2,5,6-tri-S-Glu-NE
H2, C(c")-H2), 2.04-1.93 (m, 6H, C(b)-H2, C(b')-H2, C(b")-H2) (Figure B.18 and B.19 in 
Appendix B). This component can be stnicturally identified as 2, 5, 6-tris-& 
glutathionylnorepinephrine (2,5,6-tris-5-Glu-NE), C38H56N10O21S3; M = 1084.28.
r u n  J  ‘y^N '^C O O H  
C(f>HO, 3.25 (dd, J = 14.4. 4.8 Hz, g g g g  ^
JL ^  NH " ^
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2.3.3 Cyclic voltammetric study of glutathionyl conjugates of NE
Cyclic voltammograms at v = 200 mVs"' of 2-5-Glu-NE, 5-5'-Glu-NE, 2,5-bis-.S- 
Glu-NE and 2,5,6-tris-5-Glu-NE in PBS (pH = 7.4, p = 1.0) are shown in Figure 2.6. On 
the initial anodic sweep, there are two oxidation peaks (peak I„ and peak HI,) for 5-5- 
Glu-NE, 2, S-bis-5-Glu-NE and 2,5,6-tris-5-Glu-NE; there is one oxidation peak for 2-5- 
Glu-NE (peak I,). After scan reversal, all conjugates showed reduction peaks (peak t )  
which were quasi-reversibly coupled with oxidation peaks I,. The Ep values for peaks I, of 
2-5-Glu-NE, 5-5-Glu-NE, 2,5-bis-5-Glu-NE and 2,5,6-tris-5-Glu-NE were 160 mV, 134 
mV, 140 mV and 184 mV, respectively. Except for peak I, of 2,5,6-tris-5-Glu-NE, all Ep 
values were smaller than that of NE (Ep = 179 mV). This means that glutathionyl 
conjugates of NE (except 2,5,6-tris-5-Glu-NE) are more easily oxidized than NE. The Ep 
values for the reversible peak HI, / peak lUc couples of 2-5-Glu-NE, 5-5-Glu-NE, 2,5-bis- 
5-Glu-NE and 2,5,6-tris-5-Glu-NE appeared at Ep,,/Ep.c = -196/-234 mV, -216/-250 mV, - 
192/-250 mV and -192/-242 mV, respectively, which were very close to that of NE, - 
178/-241 mV. Glutathionyl conjugates may be oxidized to o-quinone intermediates, which 
may deprotonate at the side chain of the NE moiety. The subsequent cyclization of the 
side chain may yield a trihydroxyindoline which is then oxidized by the o-quinone of 
glutathionyl conjugate of NE to yield an aminochrome. The trihydroxy- 
indolines/aminochromes are presumably responsible for the peak 111,/peak lUc couples. 
This may explain the fact that the peak in,/peak lUc couple did not completely disappear 
when NE was electroxidized in the presence of GSH. Peaks H, might be attributed to the 
further oxidation of the glutathionyl conjugates of NE.
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Figure 2.6 Cyclic voltanunograms at the PGE of 0.1 mM (A) 2-S'-Glu-NE, (B) 5^-Glu-NE. (C) 2,5-bis-S'-Glu-NE, (D) 2,5,6-tris-S’-GIu-NE 
in PBS (pH = 7.4, p = 1.0). Sweep rale; 200 mVs '.
2.3.4 Reaction Pathways
The results of cyclic voltammetric experiments indicate that GSH scavenges NE-o- 
quinone, the proximate oxidation product of NE (Figure 2.1). In controlled potential 
electrolyses of NE in the presence of GSH (molar ratio of GSH NE = 5) 5-5-Glu-NE was 
the major product along with minor yield of 2-5-GLu-NE at the initial stages of the 
oxidation reaction. Therefore, the nucleophilic attack of GSH on NE-o-quinone, 5-5-Glu- 
NE is the most favored product. Addition of GSH to the C-2 position of NE-o-quinone is 
relatively unfavorable than that of C-5 position. At the potentials corresponding to the 
foot of peak I, of NE, the initial oxidation product of NE, NE-o-quinone, is rapidly 
attacked by GSH to yield 2-5-Glu-NE and 5-5-Glu-NE. Thus the concentration of NE-o- 
quinone at the electrode surface is momentarily depleted. More NE must therefore be 
oxidized to achieve Nemstian equilibrium. Thus, instead of protecting NE from oxidation, 
GSH actually facilitates the reaction.
After prolonged controlled potential electrolyses of NE in the presence of GSH,
2,5-bis-5-Glu-NE and 2,5,6-tris-5-Glu-NE became the major products. The primary 
products from the oxidation of NE at the presence of GSH are mono-glutathionyl 
conjugates of NE, 2-5-Glu-NE and 5-5-Glu-NE. At the potential that NE is oxidized, 2-5- 
Glu-NE and 5-5-Glu-NE can also be oxidized to form the corresponding o-quinone 
intermediates, which are attacked by GSH to form 2,5-bis-5-Glu-NE. Finally, 2,5-bis-5- 
Glu-NE can again be oxidized to form 2,5-bis-5-Glu-NE o-quinone, which is attacked by 
GSH to form 2,5,6-tris-5-Glu-NE. These processes are summarized in Scheme IV.
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2.4. Autoxidation, Hydroxyl Radical-Mediated and Superoxide Anion 
Radical-Mediated Oxidation of NE in the Presence of GSH
2.4.1 Autoxidation of NE in the presence of GSH
To study the possible oxidation of NE by molecular oxygen, 0.5 mM NE was 
incubated in the presence of 5 mM GSH in PBS (pH = 7.4, p = 0.2) at 37 °C in a reaction 
vessel that was exposed to the air. The temperature was chosen to be close to human body 
temperature. After about 2 h, HPLC showed trace amounts of 2-5-Glu-NE (ta = 27.4 min) 
and 5-5-Glu-NE (ta = 33.5 min), along with significant yields of GSSG (ta = 39.5 min), in 
addition to unreacted NE (ta  = 18.4 min) and several unidentified peaks ( ta  = 10.0, 24.1, 
32.1, 34.1 and 55.8 min) (Figure 2.7 A). After 34 h of incubation at 37 °C, the GSSG 
peak was increased dramatically (Figure 2.7 B). GSSG may be formed from the oxidation 
of GSH by the oxygen dissolved in the incubation solution. During the incubation period 
between 2 h and 34 h, the concentration (measured by peak heights) of NE was reduced 
by 38%. Moreover, after 34 h of incubation, significant amounts of 2-5-Glu-NE and 5-5- 
GIu-NE were observed. Without the presence of GSH under the same conditions, NE 
formed black insoluble polymers. Therefore, at the present experiment conditions, NE is 
oxidized to NE-o-quinone, which is subsequently attacked by GSH to form the 
glutathionyl conjugates of NE.
When 0.5 mM NE was incubated in the presence of 5 mM GSH in PBS (pH = 7.4, 
p = 0.2) along with 0.2 mM Fe^ "^  (ferrous ammonium sulfate) at 37 °C, the oxidation 
reaction was accelerated. After just 10 min, the amounts of mono-glutathionyl conjugates
2-5-Glu-NE and 5-5-Glu-NE formed was noticeably larger than the same incubation in the 
absence of Fe^ * for 2 h (Figure 2.8 A). After 17 h, the concentration of NE was reduced
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Figure 2.7 Autoxidation of 0.5 mM NE in the presence of 5.0 mM GSH in PBS
(pH = 7.4, p = 0.2) at 37 °C for (A) 2 h and (B) 34 h. HPLC method I. 
Injection volume = 3.0 mL. AUFS = 0.1.
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Figure 2.8 Autoxidation of 0.5 mM NE in the presence of 5.0 mM GSH and 0.2 mM
Fe'* in PBS (pH = 7.4, p = 0.2) at 37 °C for (A) 10 min and (B) 17 h. 
HPLC method I. Injection volume = 3.0 mL. AUFS = 0.1.
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by 42%, while the concentrations of 2-5’-Glu-NE and 5-5-Glu-NE were increased by 
1200% and 1800%, respectively. Again, a very large GSSG peak was recorded after 17 h. 
As discussed in the Chapter 1, DA may produce hydrogen peroxide during the course of 
its autoxidation. The accelerated reaction by Fe^  ^ implied the involvement of hydroxyl 
radicals in the autoxidation of NE. NE is oxidized in the similar way as is DA (equations
1.3 and 1.4 in Chap. 1) to give rise to the hydrogen peroxide byproduct. Fe^ "^  will catalyze 
the conversion of hydrogen peroxide into hydroxyl radical through Fenton reaction 
(equation 1.9 in Chap. 1). Actually, iron exists as a trace contaminant in chemical reagents 
and is very diflBcult to get rid of. It is this trace amount of ¥e^*fFe^* that catalyzes the 
hydroxyl radical formation via Fenton reaction and Haber-Weiss reaction (equation 1.11 in 
Chap. 1).
2.4.2 Effects of AA and GSH concentrations on autoxidation of NE
Since the possible leakage of the capillary blood vessels in the brain could release 
hemoglobin*”  and trace amounts of low molecular weight iron*”  from erythrocytes, iron 
could be responsible for the free radical reactions in vivo. It is reported*”  recently that the 
loosely bound iron was found significantly higher in the brains of AD patients than in the 
control samples.
Because chemical reagents always contain trace amount of iron, the autoxidation 
reaction of NE may be catalyzed through HO'-mediated oxidation, as the demonstration 
reaction accelerating by adding Fe^" in the reaction media. In this section the study was 
focused on the effect of antioxidants, AA and GSH, on the oxidation of NE. 
Submicromolar concentrations of the reaction components were employed to mimic
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concentration levels in the tissue. HPLC-EC (HPLC method IH) was employed for sample 
assay. iV-methyl-5-hydroxytryptamine (N-MET) was used as an internal standard for 
quantitative measurement. The ratios of peak height of reaction components to that of N- 
MET were used to calculate the concentrations of reaction components using the 
following equation:
(2.1)
Standard
where R*unpie is the ratio of the peak height of the product to that of N-MET; R*und.rd is the 
ratio of peak height of the standard compound for the product to that of N-MET; 
Cjtandaid-is the conceutration of the standard compound for the product; C»mpie is the 
concentration of the product in the reaction mixture.
No concentration changes of NE were observed as there were no changes of peak 
height ratio of NE to N-MET. Typical concentrations of the reaction products were about
1-5% of that of NE. The peak height ratios of S-iJ-Glu-NE, 2-5-Glu-NE and 2,5-bis-5- 
Glu-NE to N-MET were linear in a range up to 1.0 pM. HPLC conditions were optimized 
to monitor the reaction products.
NE (3.0 pM) was incubated with 2.0 pM Fe^\ 24 pM EOT A in PBS (pH = 7.4, p 
= 0.2) and various amounts of AA and GSH. The reaction mixtures were kept at 37 °C in 
a water bath for 1 h. Effects of AA on reaction product yields at different concentrations 
of GSH are shown in Figure 2.10. Only mono-glutathionyl conjugates of NE were 
observed under these conditions. The molar ratio o f the 2-5-Glu-NE to 5-5-Glu-NE was 
approximately 1:2 under these conditions. When the GSH:NE molar ratio was 1, a high 
concentration of 45 pM AA virtually blocked the formation of 2-5-Glu-NE. In general, an 
increase of the AA concentration decreased the yields of glutathionyl conjugates of NE. In 
contrast to the autoxidation of NE in phosphate buffer solution, AA may prevent NE from 
oxidation by limiting the formation of NE-o-quinone, which is the target of the nucleophile
3 7
GSH. There must be a competition between the GSH and AA for the oxidation 
intermediate NE-o-quinone. GSH tends to nucleophilically attack on the o-quinone 
intermediate, while AA tends to reduce the o-quinone intermediate back to NE.
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Figure 2.9 Effect of concentration of AA on the autoxidation of 3.0 pM ME with 2.0 pM 
Fe^\ 24 pM EDTA in PBS (pH = 7.4, p = 0.2) at 37°C for 1 h in the presence 
of GSH of A) I.O pM, B) 3.0 pM, C) 5.0 pM and D) 10.0 pM. Data shown are 
the average of two independent experiments.
The effects of GSH:NE molar ratio on the autoxidation of NE at various 
concentrations of AA are shown in Figure 2.10. When concentrations of AA were at 0 
and 15 pM, yields of 2-5'-GIu-NE and 5-j'-Glu-NE were almost unaffected by different 
GSH:NE molar ratios. When AA were at 30 and 45 pM, yields of 2-&Glu-NE and 5-5- 
Glu-NE were increased when molar ratio of GSH;NE increased from 1 to 3. The yields of 
the reaction products were virtually unchanged by the GSHiNE molar ratio. Overall, the
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yields of 2-5'-GIu-NE and 5-iÿ-Glu-NE at 45 i^M AA were about the 50% of those at 
0 i^M AA. When the concentration of AA was 45 piM, the autoxidation reaction reached a 
minimum level among the experimental conditions employed. Under these conditions.
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Figure 2.10 Effect of molar ratio of GSH:NE on autoxidation of 3.0 (xM NE with 2.0 pM Fe'"" and 24 
pM EDTA in PBS (pH = 7.4, p = 0.2) at concentrations of AA = A) 0 pM, B) 15, C) 30 
pM, and D) 45 pM.
2-iS'-Glu-NE was not formed if the concentration of GSH (low molar ratio of GSH.NE) 
was low at the same time. Generally, roughly two moles of 5-5-Glu-NE were produced 
for one mole of 2-5-Glu-NE. 2-5-Glu-NE and 5-5-Glu-NE were formed in 1:2 molar 
ratio. This revealed that the C-5 position is favored twice as much as the C-2 position of 
NE-o-quinone intermediate during nucleophilic attack by GSH. This may partly be 
attributed to the fact that there is less steric hindrance effect at the C-5 position than at the 
C-2 position on NE-o-quinone.
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2.4.3 Hydroxyl radical (HO*)-mediated oxidation of NE in the presence of GSH
Hydroxyl radical (HO*) was generated by the procedure adapted from the 
l i t e ra tu reS tock  solutions of 10 mM ascorbic acid (AA), 24 mM NazEDTA, 10 mM 
Fe^ ,^ 176 mM H2O2 10 mM NE, and 10 mM GSH were prepared fresh daily. An oxidation 
reaction was started by adding: 1.0 mL AA, 0.1 mL EDTA, 0.2 mL Fe^ % 1.0 mL NE, 5.0 
mL GSH, 2.0 mL PBS (pH = 7.4, = 1.0) and 0.7 mL H2O2 Reaction timing began from
the moment of adding H2O2. The reaction mixtures were kept at ambient temperature (22 
± 2°C).
The reaction was very rapid. Thus, after 10 min incubation HPLC chromatograms 
clearly showed the formation of 2-5-Glu-NE, 5-5-Glu-NE and 2,5-bis-5-Glu-NE 
(Figure 2.9 A). It was noticed that bis-glutathionyl conjugate of NE was formed, while 
only mono-glutathionyl conjugates of NE were observed in the autoxidation experiments. 
After 75 min, even tris-glutathionyl conjugate (2,5,6-tris-5-Glu-NE) began to appear 
(Figure 2.9 B). Besides the difference in the glutathionyl conjugate products, there was a 
much lower amount of oxidized GSH (GSSG) produced in HO*-mediated oxidation of NE 
in the presence of GSH. The oxidation reaction incurred by HO* is much faster than that 
of oxygen dissolved in the solution. HO* was generated by Fenton chemistry, equation 
2.2, as shown below:
2Fe2"-EDTA + 2 H ,0 ,-----► 2Fe3*-EDTA + 2HO' + 2HO •
(2.2)
Dehydraascorbic acid Ascorbic acid
HO* is formed by decomposition of H2O2 by Fe^ ,^ and the resulting Fe^ * is then 
regenerated back to Fe^ "^  by ascorbic acid. Ascorbic acid itself is oxidized into 
dehydroascorbic acid'®*. In the reaction mixture, H2O2 is the limiting reagent. Therefore, 
the reaction stopped when no H2O2 remained. The reaction mechanism is similar to that of
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Figure 2.11 Hydroxyl radical oxidation of 1.0 mM NE in the presence of 5.0 mM GSH.
0.2 mM Fe'\ and 12 mM H2O2  in PBS (pH = 7.4, p = 0.2) at 22 °C for 
(A) 10 min, and (B) 75 min. HPLC method 1. Injection volume = 4.0 mL. 
AUFS = 1.0.
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the electrochemical oxidation of ME in the presence of GSH except that the oxidation 
condition was originated from HO* instead of electrochemical means. The much lower 
GSSG yield compared to that of the autoxidation may come from the shorter reaction time 
and the presence of AA in the reaction media.
2.4.4 Superoxide anion radical-mediated oxidation of NE in the presence of GSH
Superoxide anion radical (0 7  •) was generated by the procedure adapted from the 
literature^“ . NE (4 pM) was incubated with 20 pM GSH, 400 pM xanthine and 47 
mU/mL xanthine oxidase in 10 mL PBS (pH = 7.4, p = 0.2) at 37 °C. The reaction was 
monitored by HPLC method m . A 5.0 pL aliquot of the reaction mixture was injected 
into the HPLC system at the different time periods. The concentration of NE decreased 
rapidly during the first 10 min and remained almost constant after 10 min (Figure 2.12). 2- 
i'-Glu-NE and 5-5-Glu-NE were detected as products. However, the product peaks were 
very small and could not be measured quantitatively.
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Figure 2.12 NE peak height vs. time when 4 pM NE was oxidized in the presence of 20 
pM GSH in xanthine/xanthine oxidase superoxide anion radical generation 
system in PBS (pH = 7.4, p = 0.2) at 37 "C.
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To optimize the chromatograms for the reaction mixture, another reaction with ME 
(10 pM) was incubated with 50 pM GSH, 100 pM xanthine and 0.047 Unit/mL xanthine 
oxidase in 10 mL PBS (pH = 7.4, p = 0.2) at 37 °C. HPLC-EC Chromatograms of the 
reaction solution formed after incubation for 3 min, 36 min, and 91 min are shown in 
Figure 2.13. After 3 min incubation, 2-5-Glu-NE, 5-5-Qu-NE and 2,5-bis-5-Glu-NE were 
recorded at tR = 6.4, 9.4 and 18.8 min, respectively. Unlike under the previous conditions, the 
yields of ghxtathion^ d conjugates of NE decreased as the superoxide anion radical-mediated reaction 
continued. After 91 min incubation, peak heights of all three glutathionyl conjugates 
decreased significantly. Among them, the chromatographic peak of 2,5-bis-5-Glu-NE 
almost disappeared. Over the 91 min incubation period an unknown peak at a retention 
time of tR = 17.0 increased intensively. The retention time of this unknown peak was compared 
with the samples available in this laboratory, including 2,5,6-tris-5-Glu-NE, but this unknown 
product remains to be identified.
During the incubation, the concentration of 2-5-Glu-NE was relatively unchanged, 
while concentration of 5-5-Glu-NE already reached its maximum at or before 3 min and 
declined thereafter. 2,5-bis-5-Glu-NE was formed in the early incubation time and its 
concentration declined as the incubation continued. In the mean time, there was an 
unidentified component at tR = 17.0 min with a continuously increased peak height, in 
addition to other unknown peaks. The superoxide anion radical-mediated oxidation 
reaction of NE in the presence of GSH was different from electrochemical oxidation, 
autoxidation and HO»-mediated oxidation.
Under the experimental conditions, the Haber-Weiss reaction might contribute to 
the generation of hydroxyl radical. The buffer solution and reagents used could contain 
enough trace amounts of transition metals*®’ to catalyze the HO* formation in the presence 
of hydrogen peroxide and superoxide anion radicals. Hydroxyl radical will oxidize NE in
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Figure 2.13 HPLC-EC chromatograms of superoxide anion radical oxidation of 10 pM
ME in the presence of 50 pM GSH, 100 pM xanthine and 4.7 mUnit/mL 
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the presence of GSH the similar way as it would in autoxidation and Fenton reaction­
generated hydroxyl radical oxidation reactions. This would lead to the production of 
mono- and bis-glutathionyl conjugated NE at early incubation stage. It seemed that the 
oxidation condition generated by xanthine/xanthine oxidase system is stronger than that of 
autoxidation and HO'-mediated reaction. Therefore the glutathionyl conjugates of NE 
produced at early stage of incubation were soon be oxidized to secondary products. The 
identification of the reaction product which had a retention time of ta = 17.0 min may shed 
some light on the reaction mechanism. However, under the current conditions, it was 
difficult to collect enough to do the spectral analysis as was done on the glutathionyl 
conjugates of NE.
2.5 Discussion
In this chapter, the oxidation of NE in the presence of GSH yielded a series of 
glutathionyl conjugates of NE and thus diverted the melanin pathway. The reaction was 
carried out by means of electrooxidation, autoxidation, HO'-mediated oxidation and 
superoxide anion radical-mediated oxidation in physiological pH (pH = 7.4). Apparently, 
the electrooxidation and HO'-mediated oxidation provided the most proper conditions, 
which favored the formation of all four glutathionyl conjugates of NE. When NE was 
oxidized, the NE-o-quinone intermediate was nucleophilically attacked by GSH to form 2- 
S'-Glu-NE and 5-5-Glu-NE. 2-5-Glu-NE and 5-5-Glu-NE were more easily be oxidized 
than NE as indicated by the cyclic voltammetric study of the glutathionyl conjugates. 
Therefore, mono-glutathionyl conjugates of NE were oxidized under the same conditions 
as NE was oxidized and formed glutathionyl conjugate o-quinones. Subsequent
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nucleophilic attack by GSH yielded bis- and eventually tris-.S-glutathionyl conjugates of 
NE. When NE was auto-oxidized by the oxygen in the atmosphere, only mono- 
glutathionyl conjugates 2-5-Glu-NE and 5-5-Glu-NE were formed in a molar ratio of 
about 1:2 (2-5-Glu-NE to 5-5-Glu-NE). The superoxide anion radical-mediated reaction 
was different from other oxidation conditions. The yields of the glutathionyl conjugates of 
NE did not increase during the course of the reaction. The unknown products were 
precluded from any known glutathionyl conjugates of NE.
In recent years, increasing evidence implicates oxygen-derived free radicals with 
pathological conditions that occur in neurodegenerative diseases*®*. Superoxide radical is 
the most abundant oxygen radical generated in vivo, from sources that include activated 
leukocytes*®®, the mitochondrial electron transport chain **®, and tissue oxidases. The most 
notable oxidase is xanthine oxidase***’**^ . Xanthine oxidase catalyzes the oxidation of 
hypoxanthine and xanthine by oxygen to produce hydrogen peroxide, superoxide anion 
radical and uric acid. The xanthine oxidase is reduced by the hypoxanthine and/or 
xanthine; and the reduced xanthine oxidase then passes the electrons to molecular oxygen. 
There are two distinct pathways to pass the electrons to oxygen: monovalently (equation 
2.3) and divalently (equation 2.4), giving rise to superoxide anion radical and hydrogen 
peroxide, respectively** .^
Enzyme-Hj + 2 0 ; -----► Enzyme + 2H* + 2 0 /  (2.3)
Enzyme-Hj + -----► Oj + ^2.4)
The monovalent pathway is favored with an increased ratio of oxidized to reduced 
enzyme, such as the conditions of high concentrations of oxygen, low concentrations of 
substrate, and high pH**^ . To participate in electron transport, four redox centers in the 
active site are present in xanthine oxidase: one molybdenum, two iron-sulfrir clusters and
46
one flavin adenine dinucleotide center (FAD). The molybdenum and FAD can hold up to 
two electrons, while iron-sulfur clusters can only hold one electron'". Fully reduced 
xanthine oxidase bears six transferable electrons and reacts with excess oxygen to form a 
sequence of products in the order of H2O2, H2O2, O p a n d  0 7  Therefore,
conditions favoring a high steady state of reduction of xanthine oxidase (high xanthine 
concentration) will favor the formation of H2O2. In contrast, conditions favoring partial 
reduction of xanthine oxidase (high concentration of oxygen or high pH) favor the 
formation of superoxide anion radical.
Superoxide dismutase, AA and a-tocopherol are the main scavengers of 
superoxide anion radicals"’. Cysteine, GSH and other sulfhydryl donors are also radical 
scavengers and may act as anti-oxidants in v/vo"®’"®. GSH is an important substrate of the 
GSH-Red to convert hydrogen peroxide to water.
Superoxide anion radical and hydrogen peroxide generated from the 
xanthine/xanthine oxidase system react in the presence of certain transition metal ions, 
metal chelates, or heme proteins through the Fenton (equation 1.9) and/or Haber-Weiss 
reactions (equation 1.11) to yield hydroxyl radical. Iron is an essential species for several 
normal brain functions and trace levels of low molecular weight iron can be found in brain 
tissue"". Hydroxyl radicals will attack the nearby proteins, nucleic acids and lipids in the 
cell and may eventually cause cell death. In aqueous solution, superoxide anion radical can 
also auto-dismutate into singlet oxygen ('O2) " ’, as shown in the equation 2.5:
O ;' + HjO ► H 00-+ OH"
" ' ‘ a  ^
(HO—0 - 0 - 0 ) -  ► HOQ-+ ’O2
(2.5)
The scavengers for superoxide anion radical are more protective than the scavengers for 
hydroxyl radical and singlet oxygen. This may imply that both hydroxyl radical and singlet
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oxygen are produced secondary to the generation of superoxide anion radical*^. The 
involvement of 0% in addition to HO* might contribute to the different oxidation pattern 
of the superoxide anion radical-mediated oxidation of NE in the presence of GSH at 
physiological pH.
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Chapter 3 In Vivo Metabolism of S-.S'-Glu-NE in Rat
Brain
3.1 Introduction
In this chapter, both the in vitro and in vivo metabolisms of 5-5-GIu-NE were 
studied. The aberrant metabolites of NE were thought to be involved in the pathogenesis 
of neurodegenerative diseases like PD and AD. In vitro study has shown that a series of 
cysteinyl and glutathionyl conjugates of NE were formed when NE was oxidized in the 
presence of cysteine and GSH. Among those reaction products, at least two compounds 
from the further oxidation of the cysteinyl conjugates of NE were toxic and led to animal 
behavior changes when administered into the brains of laboratory mice®’. Since the 
concentration of GSH is larger than that of cysteine in neurons, it is conceivable that GSH 
would nucleophilically attack the NE-o-quinone when NE is oxidized under the conditions 
of oxidative stress, which is thought to be responsible for neurodegenerative diseases 
including PD and AD. The hydrolysis of 5-5-Glu-NE was studied to investigate the 
possible link between the glutathionyl conjugate of NE and cysteinyl conjugate of NE.
3.2 Experimental
3.2.1 Chemicals
L-Cysteine, L-cysteinylglycine, 3,4-dihydroxyphenylacetic acid (DOPAC), 5- 
hydroxyindole-3-acetic acid (5-HIAA), 5-hydroxytryptamine (5-HT), homovanillic acid
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(HVA), and 3,4-dihydroxybenzylamine (DHBA»HBr), and 5-hydroxytryptophan (5-HT) 
were obtained from Sigma (St. Louis, MO). A^-Acetyl-L-cysteine (NAc-Cys) was obtained 
from Aldrich (Milwaukee, WI). Sodium meta-bisulfate (NazSzO;) was obtained from 
Fisher Scientific Company Springfield, NJ. Other chemicals have been described in 
Chapter 2. All other chemicals were of highest commercially available grade and used 
without further purification.
S-^-Cysteinylnorepinephrine (5-5-.J-Cys-NE) was synthesized according to the 
literature” . 5-.y-A^-acetylcysteinylnorepinephrine (5-5-NAc-Cys-NE) and S-iî-cysteinyl- 
glycinylnoripinephrine (5-5-Cys-Gly-NE) were synthesized as described in Appendix A.
3.2.2 Instrumentation
Instruments for controlled potential electrolysis, preparative HPLC system and 
HPLC-EC system have been described in Chapter 2. A pHB0Y-P2 PET pH meter 
(Shindengen Electric Mfg. Co., Ltd, Japan) was employed to monitor the pH values when 
preparing drugs for animal experiments. A CMA/100 Microinjection Pump 
(CMA/Microdialysis AB, Stockholm, Sweden) was used for intracerebroventricular (icv) 
administration. Rat brain tissues were homogenized with a Polytron PT 1200 (Kinematica 
Ag, Switzerland) tissue homogenizer. Rat brain tissue homogenates were centrifuged 
before injection into the HPLC-EC system using a Beckman GS-15R Centrifuge 
(Beckman, Palo Alto, CA).
The preparative HPLC system and solvents (A and B) employed for HPLC 
methods IV, V, and VII were described in Chap. 2. HPLC method IV was used to isolate 
S-iî-NAc-Cys-NE. It employed solvents A and B and the following gradient profile: 0-2
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min, 0% solvent B; 2-25 min, linear gradient to 45% solvent B; 25-25.5 min, linear 
gradient to 100% B; 25.5-45 min, 100% solvent B; 45-45.01 min, linear gradient to 0% 
solvent B; 45.01-55 min, 0% solvent B. The flow rate was constant at 7.0 mL/min.
HPLC method V was used to isolate 5-&Cys-Gly-NE. It employed solvents A and 
B and the following gradient profile: 0-2 min, 0% solvent B; 2-25 min, linear gradient to 
45% solvent B; 25-25.5 min, linear gradient to 100% B; 25.5-40 min, 100% solvent B; 
40-40.01 min, linear gradient to 0% solvent B; 40.01-50 min, 0% solvent B. The flow rate 
was constant at 7.0 mL/min.
5-5-NAc-Cys-NE and 5-5'-Cys-Gly-NE were further purified by a desalting 
process through HPLC method VU. HPLC method VI employed Solvent E (deionized 
water) and F (100% MeCN) and the following gradient profile: 0-5 min, 0% solvent F; 5- 
45 min, linear gradient to 40% solvent F; 45-45.01 min, linear gradient to 0% solvent F; 
45.01-55 min, 0% solvent F. The flow rate was constant at 7.0 mL/min.
HPLC method VII was used to verify the hydrolysis process and collect the 
hydrolysis products for spectroscopic verification purposes. It employed the following 
gradient profile: 0-2 min, linear gradient to 1% solvent B; 2-25 min, linear gradient to 5% 
solvent B; 25-36 min, linear gradient to 100% B; 36-46 min, 100% solvent B; 46-47 min, 
linear gradient to 0% solvent B; 47-55 min, 0% solvent B. The flow rate was constant at 
7.0 mL/min.
HPLC-EC system and the column for HPLC methods Vm  and IX were the same 
as described in Chap. 2. In addition, ChromGraph* CONTROL 1.30 (Bioanalytical 
Systems, Inc., West Lafayette, IN) was used to control the system and collect the 
chromatograms. HPLC method VIII was used to monitor the in vitro hydrolysis process. 
The mobile phase consisted of 0.087% diethylamine (v/v), 0.050 mM EDTA, 0.48 mM 
SOS, and 0.025 M citric acid in 3.1% Methanol/deionized water. The pH value was
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adjusted to 2.37 by concentrated HCI and NaOH. The flow rate was constant at 0.6 
mL/min. HPLC method DC was used to monitor the in vivo hydrolysis process. The mobile 
phase was the same as used in HPLC method Vm. The flow rate was constant at 0.9 
mL/min.
The concentrations of 5-5-Glu-NE, 5-5-Cys-NE, and 5-5-NAc-Cys-NE were 
calculated by the equation;
C ..^ .(™ lo l/g )= .^ = ï-x 5 x C .^  (3,1)
Standard
where R^ mpic is the ratio of the peak area of the analyte to that internal standard (N-MET 
or DHBA); R«umUrd is the ratio of peak area of the standard compound to that of internal 
standard; Cjundand (pmol/L) is the concentration of the standard compound; C»mpk is the 
concentration of the analyte in the homogenate. Constant 5 in equation 3.1 comes from 
the procedure in which the homogenate was prepared by adding 5.0 pL homogenization 
solution to each milligram (mg) of rat brain tissue.
The concentrations of 5-5-Glu-NE, S-i'-Cys-NE, 5-5-NAc-Cys-NE were 
calculated by equation 3.1. Each sample was assayed by HPLC-EC system twice and the 
mean was taken for final calculation.
3.2.3 Animals
Male Sprague-Dawley rats weighing 307 to 418 g were used. Some of the rats 
(Zivic-Miller Laboratories, Inc., Zelienople, PA) were purchased with cannulas pre­
installed into their left lateral ventricles. The animals were housed 3 in each cage, while the 
pre-cannulated ones were housed individually. Rats were allowed to access to Purina rat
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chow and water ad libitum, and maintained on a 12 h light/dark cycle with lights on at 
7:00 am. Rats were not used in experiments until two weeks after receipt from the 
supplier. All animal procedures were approved by the Institutional Animal Use and Care 
Committee at the University of Oklahoma.
3.2.4 Preparation of rat brain homogenates
Rats were sacrificed by guillotine. Brains were removed and the whole brain was 
homogenized in PBS (pH = 7.4, p = 0.2) (1 mg brain tissue in 5 pL PBS) using a Polytron 
PT 1200 tissue homogenizer (Kinematica Ag, Switzerland) for 30 s at the scale of 3 
(maximum scale = 5). 5-iî-Glu-NE was added into the homogenate and then incubated at 
37 °C in a water bath. At different time period, 0.3 mL homogenate sample was taken 
from the incubation and was centrifuged at 14,000 rpm and 4 °C for 40 min. 80 pL 
supernatant was combined with 20 pL 5.0 pM N-MET. A 5 pL aliquot of the mixture 
solution (with 1.0 pM N-MET as internal standard) were injected into the HPLC-EC 
system using HPLC method VŒ.
3.2.5 Drug intracerebroventricular (icv) administration
44 nmol (21 pg) of S-S'-Glu-NE was dissolved in 5.0 pL of artificial cerebrospinal 
fluid (CSF) consisting of 147 mM NaCl, 4 mM KCl, 1.2 mM CaCU, and 1.2 mM MgS0 4  
in deionized water. The pH of the drug solution was adjusted to neutral (pH = 7.0 ± 0.5) 
by NaOH solution.
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For pilot experiments, rats were anesthetized with a mixture of ketamine (50 
mg/kg) and xylasine (4 mg/kg) administered intraperitoneally (ip) and were then placed in 
a stereotaxic apparatus with the incisor bar positioned 3.3 mm below the interaural line. A 
small hole was made with a hand-held drill on the leveled skull using the coordinates; AP -  
0.8 mm and L + 1.4 mm relative to bregma. Drugs were injected by means of a 10 pL 
Hamilton microsyringe equipped with a 31 gauge needle, the tip of which was lowered 3.6 
mm ventral to bregma. A 5.0 pL injection was made over a period of 2 min, the needle 
being maintained in place for an additional 1 minute before withdrawal. Timing was 
started upon the completion of the drug injection.
For the rest of the experiments, guide cannulas were pre-installed into the left 
lateral ventricles of rats. Drugs prepared as described above were infused into left lateral 
ventricles through the cannulas. A CMA/100 Microinjection Pump coupled with a 50 pL 
Hamilton microsyringe was used to deliver the drugs. 5.0 pL aliquots of drug solution 
were infused over a period of 2 min and timing was started at the end of this time. 
Meanwhile, the infusion tube remained in place for an additional 2 min before withdrawal.
5, 15, 30, 60, and 120 min after icv administration of 5-iî-Glu-NE rats were 
sacrificed by guillotine decapitation. Brains were removed and dissected into striatum, 
midbrain, hippocampus, medulla/pons and cortex on an ice-chilled glass plate. Each brain 
part was immediately wrapped in aluminum foil and frozen in liquid nitrogen ( -  78 °C). 
Brain tissues were then store at -  80 °C in a refrigerator until assayed.
Immediately prior to HPLC-EC analysis, brain tissues were weighed and 
homogenized in a homogenization solution (0.1 M HCIO4, 134 pM NazEDTA, 263 pM 
Na2S20s, and 1.0 pM DHBA). DHBA was added into the homogenization solution as an 
internal standard. 5.0 pL homogenization solution was added to 1 mg brain tissue. Brain 
tissues were homogenized with a Polytron PT-1200 tissue homogenizer with a speed scale
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adjustable from 1 to 6. Tissues were first blended at the lowest speed (for about 10 s) and 
then at speed scale of 3 (5 for cortex tissue) for an additional 20 s. The resulting 
homogenates were centrifuged at 14,000 rpm for 60 min at 4 °C and kept at 0 °C on ice. 
A 5 pL aliquot of supernatant was injected directly into HPLC-EC system for analysis.
The concentrations of 5-5-Glu-NE, 5-5-Cys-NE, 5-5-NAc-Cys-NE were 
calculated by equation 3.1. Each sample was assayed by HPLC-EC system twice and the 
mean was taken for final calculation.
3.3 In Vitro Metabolism of S-iS-Glu-NE
3.3.1 Hydrolysis of S-.S'-Glu-NE in rat brain homogenate
The in vitro hydrolysis of S-iî-Glu-NE was first studied by adding 30 nmol of 5-5- 
Glu-NE into 5 mL rat brain homogenate (sample A). A 5 mL rat brain homogenate was 
used as a control (sample B). Two samples were incubated at 37 °C in a water bath. An 
HPLC peak appeared at retention time ta = 18.5 min, (Figure 3.1 lA) before the 
incubation started. After 1 h incubation, a new HPLC peak appeared at retention time ta =
13.5 min. During the 6 h incubation, peak at ta = 18.5 min decreased and disappeared at 
the end of the incubation, while peak at ta = 13.5 min increased and reached maximum at 
the end of 6 h incubation (Figure 3.1 5 A). Comparing the retention times of the two peaks 
with standard sample, the peak at ta = 18.5 min corresponded to 5-5-Glu-NE and the peak 
at ta = 13.5 min was corresponded to 5-5-Cys-NE. In contrast, there were no peaks 
observed at retention times of ta = 13.5 and 18.5 min throughout the incubation period 
(Figure 3.1 IB to 5B). However, there was an HPLC peak at ta = 13.3 min, close to 5-5-
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Figure 3.1 30 nmol 5-5-G!u-NE incubated in 5 mL rat brain homogenate at 37 °C for I A) 0 h. 2A)
I h, 3A) 2 h. 4A) 3 h, and SA) 6 h. 5 mL rat brain homogenate at 37 °C for 1B) 0 h.
23) 1 h, 33) 2 h. 43' 3 h. and 53) 6 h. HPLC method VII. Injection volume = 5 pL.
5 6
Cys-NE peak, at the beginning of the incubation in both sample A and B. It disappeared 
during the incubation period and its identity remained unknown. Other peaks were 
presumably electroactive neurotransmitters and their metabolites. The current conditions 
were only optimized to separate the NE conjugates from other components in the rat brain 
homogenates.
The above incubation was repeated with 50 nmol 5-5-Glu-NE in 5 mL rat brain 
homogenate. The results are summarized in Figure 3.2. It took a longer time to convert all 
the 5-5'-Glu-NE into the S-j"-Cys-NE in the second incubation as expected.
2
1.5-
0.0
0.0 0.5 1.0 2.0 2.5 3.01.5
Time/h
Figure 3.2 Peak heights (relative to N-MET) during the incubation of (A) 30 (dotted line)
and (B) 50 (solid line) tunol S-S-Glu-NE in 5 mL rat brain homogenate in PBS 
(pH = 7.4, u = 0.1) at 37 °C.
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3.3.2 Structural confirmation of 5>>S'-Cys-NE
To further confirm the formation of 5-5-Cys-NE from the in vitro hydrolysis o f 5- 
5-Glu-NE, 2.7 mg 5-5-Glu-NE was added to 20 mL rat brain homogenate (ca. 3.3 g brain 
whole brain tissue, pH = 7.4) and incubated at 37 °C. The hydrolysis was completed in 8 
h. After centrifugation, the supernatant obtained from the homogenate was injected 
directly into a preparative HPLC system using HPLC method VII. The HPLC peak at 
retention time ta = 13.3 min (Figure 3.3) was confirmed to be 5-5-Cys-NE by comparing 
its retention time and UV-Vis spectrum (Figure 3.4) with those of the authentic sample. 
Other HPLC peaks under the same condition were not identified. They might be proteins 
in the homogenates, since a UV detector was used in the HPLC system. The eluent
0.6 OH
HO NH.
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Figure 3.3 Preparative HPLC chromatogram of 20 mL rat brain homogenate incubated with 
2.7 mg 5-S’-Glu-NE in PBS (pH = 7.4, p = 0.1) at 37 °C for 8 h. HPLC method 
Vn. Injection volume 1.0 mL. AUFS = 1.0.
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Figure 3.5 'H NMR spectrum (in D^O) of 5-À'-Cys-NE isolated from rat brain homogenate incubated with 5-.V-Glu-NE in PBS (pH = 7.4, 
H = 0.1) at 37 “C.
collected under the HPLC peak at ta = 13.3 min was frozen on dry ice. The sample was 
later freeze-dried. NMR spectrum was obtained from the white solid isolated from the 
homogenate without further purification. 'H NMR (D2O) gave 5 7.23 (s, IH, C(2)-H), 
7.09 (s, IH, C(6)-H), 5.01 (dd, J = 8.0, 4.0 Hz, IH, C(a)-H), 4.02 (dd, J = 7.3, 4.9 Hz, 
IH, C(b)-H), 3.60 -  3.28 (m, 4H, C(P)-H2, C(a)-H2) (Figure 3.5).
It is concluded that 5-5’-Glu-NE was hydrolyzed into 5-5-Cys-NE in rat brain 
homogenate at physiological pH. However, the search for other possible metabolites, for 
example, 5-5'-Cys-Gly-NE and 5-5-NAc-NE was unsuccessful.
3.4 In vivo metabolism of S-^-GIu-NE
3.4.1 lev administration of S-5'-Glu-NE in rat brain
5 rats were used in each group at different periods of time. 44 nmol (21 pg) of 5- 
5-Glu-NE dissolved in 5 pL artificial CSF was administered into the left lateral ventricle of 
the rats through pre-installed cannulas. The rats were sacrificed 5, 15, 30, 60 and 120 min 
after icv administration. 5 rats were used in each experimental group, while 4 rats were 
used as the control group. The rats of control groups were sacrificed 30 and 120 min after 
the infusion of the artificial CSF. HPLC method EX was employed for the sample assay. In 
addition, one-way analysis of variance (ANOVA) was used to calculate the statistical 
significance (P value) at 95% confidence limit.
Typical HPLC-EC chromatograms from the striatum, midbrain, hippocampus, 
cortex and medulla/pons 15 min after icv administration of 44 nmol 5-5’-Glu-NE are 
shown in Figure 3.6. After icv administration of 5-&Glu-NE, 5-5-Cys-NE and 5-5'-NAc-
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Cys-NE were detected as metabolites of 5-5-Glu-NE. The retention times of each HPLC
peak are summarized in Table 3.1.
Table 3.1 Summary of Retention Time of Rat Brain Tissue after Icv 
Administration of 5-£-Glu-NE
Component Retention time (min)
S-S-NAc-Cys-NE 9.0
S-S-Cys-NE 14.0
5-S^Glu-NE 33.8
DHBA 6.2
NE 3.0
DOPAC 4.2
5-HIAA 8.2
DA 10.6
HVA 12.2
5-HT 36.5
3.4.2 In vivo metabolism of M-Glu-NE in rat brain.
The quantitative results of metabolism of 5-5-Glu-NE in striatum, midbrain, 
hippocampus, cortex and medulla/pons of the rat brain are summarized in Figures 3.7 — 
3.11, respectively. Data are represented as mean ± standard error (SE).
In all brain regions except the cortex, 5-5-Glu-NE was cleared within 15 min. 
However, it took about 1 h to clear the 5-&Glu-NE in the cortex. The concentrations 5-S- 
Glu-NE were found highest at 5 min after icv administration in the brain regions in the 
order of medulla/pons (1.52 nmol/g), midbrain (1.31 nmol/g), striatum (1.14 nmol/g), 
hippocampus (1.02 nmol/g) and cortex (0.80 nmol/g).
5-5-Cys-NE was formed as a metabolite as expected. The maximum 
concentrations of 5-5'-Cys-NE in striatum and midbrain were 7.54 nmol/g and 5.78 
nmol/g, respectively, which were reached 15 min after icv administration of 5-5'-Glu-NE 
and declined by 60% and 85% (compared to the maximum level) 120 min after icv
64
ONLA
D)
O
Ec
co
- w
2
•4—»
C
8co
ü
striatum
—□— 5-S-NAc-Cys-NE 
—# — 5-S-C^s-NE 
—A— 5-S-GI ü-NE
40 60 80
Time/min
1 0 0  1 2 0
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Figure 3.8 Rat midbrain after icv administration of 44 nmol (21 ng) 5-S-Glu-NE, Each data point represents the mean ± SE of 5 rats.
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Figure 3.9 Rat hippocampus after icv administration of 44 nmol (21 pg) 5-5-GIu-NE. Each data point represents the mean ± SE of 5 rats.
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Figure 3,11 Rat medulla/pons after icv administration of 44 nmol (21 pg) 5-S-Glu-NE. Each data point represents the mean ± SE of 5 rats.
administration of 5-5-Glu-NE. In the hippocampus and medulla/pons the maximum 
concentrations of 5-5-Cys-NE, 7.41 nmol/g and 6.53 nmol/g, were reached 30 min after 
icv administration of 5-5-Glu-NE. The concentrations of 5-5'-Cys-NE declined from the 
maximum levels by 54% and 50%, respectively, 120 min after icv administration of 5-S- 
Glu-NE. The maximum concentration of 5-5'-Cys-NE in the cortex, 4.95 nmol/g, was 
reached at 60 min, the slowest among all areas of the brain in terms of the time required to 
reach the maximum concentration. In the next 1 h, 5-5-Cys-NE decline 68% in the cortex.
The last hydrolysis intermediate detected in the current experimental condition was 
5-S-NAc-Cys-NE. It was formed in all brain regions at the shortest icv administration time 
(i.e., 5 min). The concentrations in these areas were, from the highest concentration to the 
lowest, 1.37 nmol/g (striatum), 1.28 nmol/g (midbrain), 0.81 nmol/g (hippocampus), 0.64 
nmol/g (cortex) and 0.43 nmol/g (medulla/pons). In cortex, the concentration of 5-5'-NAc- 
Cys-NE reached its maximum at 4.08 nmol/g and then reduced by 55% 1 h later. 
Contrarily, the concentration of 5-6"-NAc-Cys-NE continued to grow, except the 
concentration momentarily went down at 15 min in striatum and 60 min in midbrain. The 
final concentrations of 5-5’-NAc-Cys-NE were increased (compared to the initial value at 5 
min) by 1.64 times in striatum, 5.65 times in midbrain, 4.89 times in hippocampus and
10.5 times in medulla/pons. Even in the cortex, the final concentration of 5-5-NAc-Cys- 
NE was still 2.89 times the initial level.
3.4.3 Effect of icv administration of 5>.$-Glu-NE on neurotransmitter levels
A. Dopaminergic system
DOPAC and HVA are the metabolites of DA. The concentrations of DA,
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DOPAC and HVA in ail five brain regions following icv administration of 5-5-GIu-NE are 
shown in Figures 3.12- Figure 3.16.
In the striatum and medulla/pons, there were no significant changes in the 
concentrations of DA, DOPAC and HVA and (Figure 3.12 and 3.16).
In the midbrain the concentration of HVA was decreased by 33% (p < 0.01) 
compared with controls 120 min after icv administration of S-iS-Glu-NE, with no 
significant changes on the concentrations of DA and DOPAC (Figure 3.13).
In the hippocampus the concentration of DA was decreased by 50% (p < 0.05) 
after 120 min icv administration. No significant changes for DOPAC and HVA were 
observed in this brain region (Figure 3.14).
Last, in the cortex, the concentration of DA was increased by 20% (p < 0.05) after 
120 min icv administration. No significant changes were observed on DOPAC and HVA 
(Figure 3.15).
B. Serotonergic system
5-HT is also called serotonin. In neurons, L-tryptophan is oxidized through 
tryptophan hydroxylase to L-5-hydroxytryptophan, which metabolizes to 5-HT through 5- 
hytroxytryptophan decarboxylase. 5-HT is oxidized by MAO to form 5- 
hydroxyindoleacetaldehyde, which converts to 5-hydroxyindoleacetic acid (5-HIAA) by 
aldehyde dehydrogenase.
The concentration changes of 5-HT and 5-HIAA during icv administration of 44 
nmol 5-5-Glu-NE are shown in Figures 3.17 - Figure 3.21. In all brain regions, the 
concentrations of both 5-HT and 5-HIAA were increased 30 min after icv administration 
of 5-5'-Glu-NE, except that 5-HT was decreased in the hippocampus in the same time 
period (Table 3.2).
7 6
Table 3.2 Concentration Changes (%) in Rat Brain during the First 30
min after lev Administration of 44 nmol S-S'-Glu-NE.
Area 5-HT 5-HIAA
Striatum 44 65
Midbrain 4 37
Hippocampus -10 127
Cortex 30 59
Medulla/pons 13 54
The levels of 5-HT and 5-HIAA were significantly increased in all brain regions 
compared to those of the controls 30 min and 120 min after icv administration 5-5-Glu- 
NE.
In the striatum the concentration of 5-HIAA increased by 40% (p < 0.05) 30 min 
after icv administration 5-5'-Glu-NE, while the concentration of 5-HT increased by 51% (p 
< 0.005) 30 min after icv administration of 5-&Glu-NE and 48% (p < 0.05) at 120 min 
after icv administration 5-,S'-Glu-NE (Figure 3.17).
In the midbrain, the level of 5-HIAA increased 38% (p < 0.05) and 33% (p < 
0.05), separately, 30 min and 120 min after icv administration of 5-5-Glu-NE. 5-HT 
increased 38% (p < 0.01) 30 min after icv administration of 5-5-Glu-NE (Figure 3.18).
In the hippocampus, levels of 5-HIAA and 5-HT increased 35% and 30%, 
respectively, 30 min after icv administration 5-5-Glu-NE, while no significant change was 
seen after 120 min (Figure 3.19).
In the cortex, the level of 5-HIAA increased 29% (p < 0.01) after 30 min and 33% 
(p < 0.05) after 120 min. The level of 5-HT increased 65% (p < 0.05) at 30 min while the 
change at 120 min without significant difference (Figure 3.20).
Finally, in the medulla/pons, the level of 5-HIAA increased 50% (p < 0.05) at 30 
min and 35% (p < 0.01) at 120 min. The level of 5-HT increased 38% (p < 0.005) at 30 
min and 32% (p < 0.05) at 120 min (Figure 3.21).
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(middle) and 120 min (bottom). Each data point represents the mean ± SE of 4-5 
rats.
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Figure 3.18 Effect of icv administration of 44 nmol (21 ng) 5-5’-Glu-NE on the concentrations 
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Effect of icv administration of 44 nmol (21 pg) 5-5-Glu-NE on the concentrations 
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4-5 rats.
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c .  Noradrenergic system
NE is synthesized in the cell body or in the synaptic terminal from DA through the 
catalysis of dopamine-6-hydroxylase. NE is also oxidized by MAO. In the current 
experimental condition, only NE itself was detectable.
Concentrations of NE in various brain regions following icv administration of 5-S- 
Glu-NE are shown in Figure 3.22. The only significant changes observed were a 35% 
increase (p < 0.05) in the striatum 120 min and a 14% increase (p < 0.05) in the midbrain 
30 min after icv administration of 5-5'-Glu-NE.
3.5 Discussion
The experimental results in this chapter demonstrate that 5-5-GIu-NE can be 
metabolized to form 5-5-Cys-NE in vitro and metabolized to 5-^-Cys-NE and 5-&NAc- 
Cys-NE in vivo. The formation of 5-5-Cys-NE and 5-S'-NAc-Cys-NE was confirmed by 
comparing the brain tissue homogenate with the authentic samples on HPLC systems. The 
formation of the metabolite 5-iS-Cys-NE was further structurally confirmed by 
spectroscopic methods, i.e., UV-Vis and 'H NMR.
The first step in the metabolism of glutathionyl conjugate of NE is the removal of 
the y-glutamyl group by y-glutamyl transpeptidase (y-GT). y-GT is a membrane bound 
enzyme with its active site directed toward outside of the cell. Therefore the cleavage of 
the y-glutamyl group occurred extracellulary. The cysteinylglycinyl conjugate of NE is 
converted to the cysteinyl conjugates of NE by dipeptidase(s). '^-Cysteinylglycinyl 
conjugates may serve as substrates for several different peptidases. Aminopeptidase M and 
a dipeptidase have been suggested as the primary enzymes responsible for the metabolism
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Figure 3.22 EfFect of icv administration of 44 nmol (21 gg) 5-5-Glu-NE on the concentrations 
of NE in rat brains; 30 min (top) and 120 min (bottom). Each data point 
represents the mean ± SE of 4-5 rats.
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of 5-cysteinylglycinyI conjugates’” ’*^'*. Finally, the formation of 5-5-NAc-Cys-NE is 
mediated by cysteine conjugate A^-acetyltransferase and A'^acetyi-cysteine conjugate N~ 
deacetylase. The metabolism of 5-5-Glu-NE is summarized in Scheme V.
Scheme V
OH OH
H O y - 5 . J s ^ N H 2  H O y ^ Y ^ N H ;
H O 'V ^ y-GT H O " ^
O S ^ 2  f  + Glutamate
H O O C - p i Y
 ^ o  5-S-Cys^ly-NE
5-S-Glu-NE I D'peptidase(s) OH t  OH
Cysteinyl conjugate H O y /^ y Y /N H ^  
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S  ► S  + Glycine
H gC yW yJ /V-ac6ty jcysteiny I H^Nyxl
O COOH conjugate |
AAdeacetyiase COOH
5^-NAc-Cys^E 5^-Cys^E
Under in vitro conditions, however, the hydrolysis metabolite S-&-NAc-Cys-NE 
was not found as a metabolite of 5-&Glu-NE. The reason may be attributed to the loss of 
activities of the related enzymes and their cofactors during homogenate preparation.
The effect of icv administration of 5-5-Glu-NE on neurotransmitter levels varies. 
For the dopaminergic system, 120 min after icv administration of 5-.J-Glu-NE, DA levels 
were significantly decreased by 50% (p < 0.05) in the hippocampus and increased by 20% 
(p < 0.05) in the cortex. Levels of DA metabolite HVA were significantly decreased by 
33% (p < 0.01) 120 min after icv administration of 5-S-Glu-NE.
Levels of 5-HIAA or 5-HT or both were significantly increased (from p < 0.05 to 
p < 0.005) in all brain regions either 30 min or 120 min after icv administration of 5-5- 
Glu-NE.
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Levels of NE were significantly increased by 14% (p < 0.05) in midbrain 30 min 
after icv administration of S-iî-Glu-NE and by 35% (p < 0.05) in striatum 120 min after 
icv administration of 5-iS'-Glu-NE.
These observations suggest a general increase in noradrenergic and serotonergic 
activity in rat brain and various changes of dopaminergic activities in different rat brain 
regions.
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Chapter 4 In Vivo Metabolism of S-J-Glu-DA in Rat Brain
4.1 Introduction
In this chapter the investigation was focused on the metabolism of glutathionyl 
conjugates of DA under in vitro and in vivo conditions. A key step in the hypothesis is 
that the elevated influx of GSH or cysteine into SN neurons would divert the 
neuromelanin pathway causing depigmentation of the SN. GSH (or cysteine) attacks the 
oxidation intermediate, DA-o-quinone, to yield glutathionyl (or cysteinyl) conjugates. It is 
most likely that GSH would attack the DA-o-quinone first, since GSH has a larger 
concentration than cysteine in neurons. The subsequent glutathionyl conjugates of DA 
would be hydrolyzed to give rise to cysteinyl conjugates of DA. In vitro studies showed 
that the oxidation potentials of cysteinyl conjugates of DA are more negative than that of 
DA. Therefore, it is reasonable to assume that, in the same location where DA is auto­
oxidized to neuromelanin, cysteinyl conjugates of DA, if formed, would likely be oxidized 
to give rise to further oxidative metabolites. Electrochemical studies show that cysteinyl 
conjugates of DA are easily oxidized to form a series of dihydrobenzothiazines (DHBTs) 
at physiological pH (Scheme II in Chap. 2). Preliminary biological studies show that 
DHBTs are lethal to laboratory mice and caused neurobehavioral effects as well^. Both 
the in vitro and in vivo metabolism of glutathionyl conjugates of DA were studied.
4.2 Experimental
4.2.1 Chemicals
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Dopamine hydrochloride (DA»HC1) was obtained from Sigma (St. Louis, MO). 5- 
5-CysteinyIgIycine-DA (5-5’-Cys-Gly-DA) was provided by Dr. Xueming Shen from this 
laboratory. 5-.?-Cysteinyldopamine (5-5'-Cys-DA), 5-5'-gIutathionyldopamine (5-5'-Glu- 
DA), 5-A/-acetyl-cysteinyIdopamine (5-5-NAc-Cys-DA) were prepared according to 
literature procedures*®*®’’*^. In brief, 1 mM DA in 0.1 M HCl was electrolyzed at 1.0 V 
for 60 min resulting a bright yellow solution. The solution became a pale yellow in color 
immediately when GSH (molar GSH.DA = 5:1) was added. The reaction mixture was 
injected into HPLC system using HPLC method X. 5-5-Glu-DA was collected, frozen on 
dry ice and freeze-dried. The same procedure was repeated by substituting GSH with L- 
cysteine and A-acetyl-L-cysteine separately to produce the corresponding conjugates of 
DA. HPLC method XI and XII were employed for the isolation of cysteinyl, and N- 
acetylcysteinyl conjugates of DA Each white solid was dissolved in a minimum amount of 
deionized water and purified (desalting) by HPLC method VI. Other chemicals have been 
described in Chap. 2 and 3. All other chemicals were of highest commercially available 
grade and used without further purification.
4.2.2 Instrumentation
Instruments for controlled potential electrolysis, preparative HPLC system, and 
HPLC-EC system have been described in Chap. 2 and 3.
Preparative HPLC system and solvents (A and B) employed for HPLC methods X  
XI, and XU were described in Chap. 2. HPLC method X was used to isolate 5-5-GSH- 
DA. It employed the following gradient profile: 0-2 min, 0% solvent B; 2-20 min, linear 
gradient to 30% solvent B; 20-35 min, linear gradient to 100% B; 35-45 min, 100%
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solvent B; 45-46 min, linear gradient to 0% solvent B; 46-50 min, 0% solvent B. The flow 
rate was constant at 7.0 rnL/min.
HPLC method XI was used to isolate 5-5-Cys-DA. It employed the following 
gradient profile: 0-2 min, 0% solvent B; 2-25 min, linear gradient to 28% solvent B; 25-
25.5 min, linear gradient to 100% B; 25.5-35 min, 100% solvent B; 35-35.01 min, linear 
gradient to 0% solvent B; 35.01-45 min, 0% solvent B. The flow rate was constant at 
7.0 mL/min.
HPLC method XII was used to isolate 5-5-NAc-Cys-DA. It employed the 
following gradient profile: 0-2 min, 0% solvent B; 2-25 min, linear gradient to 45% 
solvent B; 25-25.5 min, linear gradient to 100% B; 25.5-40 min, 100% solvent B; 40-
40.01 min, linear gradient to 0% solvent B; 40.01-50 min, 0% solvent B. The flow rate of 
was constant at 7.0 mL/min.
HPLC method XM employed an HPLC-EC system as described in Chap. 2 and 3. 
The mobile phase consisted of 0.084% diethylamine (v/v), 0.055 mM EDTA, 0.46 mM 
SOS, and 0.10 M citric acid in 6.2% ACN/deionized water. pH was adjusted to 2.37 by 
concentrated HCl and NaOH. The flow rate was constant at 0.6 mL/min.
Data treatment and the calculation of concentrations of 5-J-Glu-DA, 5-5'-Cys-DA, 
5-.y-NAc-Cys-DA and 5-5-Cys-Gly-DA were described in Chap. 3.
4.2.3 Animals
Male Sprague-Dawley rats weighing fi’om 300 — 386 g were used. Other 
conditions were described in Chap. 3. All animal procedures were approved by the 
Institutional Animal Use and Care Committee at the University of Oklahoma.
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4.2.4 Preparation of rat brain homogenates
The preparation of rat brain homogenates was described in Chap. 3. HPLC-EC 
system using HPLC method Xm  was employed for sample assay.
4.2.5 Icv administration of DA conj ugates
44 nmol of drug (i.e., 20 pg 5-5-Glu-DA, 11.8 pg 5-5'-Cys-DA, and 4.8 pg 5-5- 
Cys-Gly-DA, separately) was dissolved in 5.0 pL of artificial CSF. Rats were sacrificed 5, 
15, 30, 60, and 120 min after icv administration of 5-5-Glu-DA; 15, 30, 60 and 120 min 
after icv administration of 5-5-Cys-DA; and 5, 30, and 60 min after icv administration of 
5-5-Cys-Gly-DA. Three rats were used at each time period for icv administration of 5-5- 
Glu-DA and 5-5-Cys-DA, while one rat was used for each time period for icv 
administration of 5-5-Cys-Gly-DA Other procedures were the same as described in Chap. 
3.
4.3 In Vitro Metabolism of Glutathionyl Conjugates of DA in Rat 
Brain Homogenates
4.3.1 Hydrolysis of 5-5-Glu-DA in rat brain homogenates
10 pL of 1.0 mM 5-5-Glu-DA was added into 10 mL (ca. 1.7 g whole brain tissue) 
rat brain homogenate and then incubated at 37 °C on a water bath. Immediately after
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adding 5-5-Glu-DA to the homogenate a 0.5 mL aliquot of sample was taken and 
centrifuged at 14,000 q>m and 4 °C for 40 min. A 5 pL aliquot of the supernatant was 
injected into HPLC-EC system using HPLC method XUI. The chromatogram of the 
supernatant showed two peaks at retention times of ta = 9.1 and 13.2 min (Figure 4.1 A), 
identical to the retention times obtained with authentic samples of 5-5-Cys-DA and 5-5- 
Glu-DA under the same conditions. After 30 min incubation, almost all 5-5-Glu-DA was 
converted to 5-5-Cys-DA with little 5-5-Glu-DA remaining (Figure 4.1 B). After 60 min 
incubation, HPLC-EC chromatogram showed only the peak of 5-5-Cys-DA.
These chromatograms demonstrate the hydrolysis process of 5-5-Glu-DA at 
physiological pH in rat brain homogenate. The hydrolysis may involve y-glutamyl 
transpeptidase to clip the glutamyl residue from the GSH moiety to give rise to 5-5-Cys- 
Gly-DA which may be further metabolized by a dipeptidase enzyme to remove the glycinyl 
residue to form 5-5-Cys-DA. The hydrolysis of 5-5-Glu-DA must have occurred very fast. 
Since there was no special treatment to stop the activities of enzymes in the homogenate, 
the enzymes responsible for the hydrolysis may still be active at 4 °C during the 
centrifugation. The real hydrolysis process may be slightly slower than that shown in 
Figure 4.1, if the extra 40 min at 4 °C were taken into account. These results demonstrate 
for the first time that glutathionyl DA could be hydrolyzed in vitro into cysteinyl DA. 
However, the effort trying to identify other possible intermediates, e.g., 5-5-NAc-Cys-DA 
and DHBTl (Scheme II in Chap. 1), failed to obtain any positive results.
The experiment in this section concludes that 5-5-Glu-DA can be hydrolyzed into 
5-5-Cys-DA in vitro at rat brain homogenate at physiological pH 7.4 and 37 °C and 5-5- 
Cys-DA is the only confirmed product in this process.
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Figure 4 I HPLC-EC chromatograms of 10 pL 1.0 mM 5-S'-Glu-DA incubated in 10 mL 
rat brain homogenate in PBS (pH = 7.4. p. = 0.1) at 37 °C. HPLC method XIII. 
Injection volume = 5 pL.
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Figure 4.2 20 nmol 2.5-bis-S-Glu-DA incubated in 5.0 mL rat brain homogenate
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h. HPLC method XIII. Injection volume = 5 pL.
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4.3.2 In vitro metabolism of 2,S-bis-&Glu-DA in rat brain homogenate.
2,5-bis-5-GIu-DA is one of the major products, along with 5-5-Glu-DA and 2,5,6- 
/r/j-5-Glu-DA, at the initial stage of electro-oxidation of DA in the presence of the GSH 
at physiological ptfV
20 pL of 1.0 mM 2,5-bis-5-Glu-DA was added to 5.0 mL rat brain homogenate 
and incubated at 37 °C in a water bath. A piece of parafilm was used to seal the vial 
to prevent the homogenate from evaporating during the incubation. 2,5-bis-5-Glu-DA 
was eluted at retention time ta = 20.7 min. N-MET was added into the homogenate as an 
internal standard and eluted at retention time ta = 13.3 min. The expected metabolite, 2,5- 
bis-5-Cys-DA, did not appear (Figure 4.3 A and B) until after 3 h incubation and was 
eluted at retention time ta = II .5 min (Figure 4.3 C). The changes of peak heights of 2,5- 
bis-5-Cys-DA and 2,5-bis-5-Glu-DA relative to N-MET (internal standard) are 
summarized in Figure 4.4.
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Figure 4.3 Changes of peak heights (relative to N-MET) of 2,5-bis-5-Cys-DA and 
2,5-bis-5-GIu-DA during incubation of 20 nmol of 2,5-bis-5’-Glu-DA 
with 5.0 mL rat brain homogenate in PBS (pH = 7.4, p = 0.1) at 37 °C.
During the first 2 h incubation, the concentration of 2,5-bis-5-Glu-DA decreased
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rapidly without a concomitant increase in the yield of 2,S-bis-&Cys-DA. After 2 h 
incubation, the decrease of the concentration of 2,5-bis-5'-GIu-DA slowed down and 2,5- 
bis-5-Cys-DA began to form. There were 3 peaks which remained unidentified. One of the 
unknowns appeared at a retention time ta = 12.1 min momentarily (Figure 4.2 B and C) 
and disappeared later (Figure 4.2 D). The second unknown peak eluted at a retention time 
ta = 10.7 min and stayed at a constant level. The third unknown peak eluted at a retention 
time ta = 21.8 and grew steadily with the incubation time (Figure 4.2).
It is also possible that the unknown peaks might be one of the products from the 
further oxidation of the hydrolysis product 2,S-bis-&Cys-DA (Scheme U). Therefore, the 
retention times of those unknown peaks were compared to those of DHBTs. 
Unfortunately, none of the retention time of the unknown peaks matched those of DHBTs. 
The retention times are listed in Table 4.1.
Table 4.1 Retention Times for the Peaks during in vitro 
Metabolism of 2,S-bis-5-Glu-DA in Rat Brain 
Homogenate.
Compound Name Retention Time/min
2,5-bis-.S-GIu-DA 20.7
2,5-bis-S'-Cys-DA 11.5
N-MET (internal standard) 13.3
Unknown peak 1 10.7
Unknown peak 2 12.1
Unknown peak 3 21.8
DHBT2 27.0
DHBT3 16.5
To conclude, the in vitro metabolism of 2,5-bis-iÿ-Glu-DA in rat brain homogenate 
at physiological pH 7.4 and 37 °C yielded the 2,5-bis-5-Cys-DA together with other 
unidentified metabolites.
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4.4 In Vivo Metabolism of S^S-Glu-DA in Rat Brain
4.4.1 lev administration of 5-5-GIu-DA
44 nmol (20 ^g) of 5-5-Glu-DA was infused into the left lateral ventricles through 
cannulas pre-installed on rats as described in Chap. 3. The rats were sacrificed 5, 15, 30, 
60 and 120 min after icv administration. 3-4 rats were used as a group for each of the 
different periods of time. HPLC-EC method Xm  was employed to monitor the hydrolysis 
process. Each sample was injected into the HPLC-EC system twice and the average was 
taken. The concentration was calculated by equation 3.1 (Chap. 3). The mean and 
standard error (SE) of a group of animal were calculated.
Typical HPLC chromatograms shown in Figure 4.4 were obtained fi’om tissues of 
the striatum, midbrain, hippocampus, cortex and medulla/pons of a rat brain 15 min after 
icv administration of 44 nmol 5-5-Glu-DA. Data of the complete in vivo experiment are 
summarized in Figure 4.5 to 4.9.
5 min after icv administration the concentration of 5-5-Glu-DA was found highest 
in the striatum (4.08 nmol/g), followed by hippocampus (3.13 nmol/g), medulla/pons (2.47 
nmol/g), midbrain (2.44 nmol/g) and cortex (1.62 nmol/g). 5-5-Glu-DA disappeared from 
striatum within 30 and all other areas within 60 min.
Unlike the in vitro metabolism of 5-5-Glu-DA, the dipeptidyl metabolite 5-5-Cys- 
Gly-DA was detected during the in vivo metabolism of 5-5-Glu-DA. It appeared during 
roughly the same time window as 5-5-Glu-DA could be detected. Therefore, 5-5-Cys-Gly- 
DA appeared at highest levels 5 min after icv administration with concentrations in each 
brain area in the order hippocampus (0.77 nmol/g) > striatum (0.72 nmol/g) > midbrain 
(0.67 nmol/g) > medulla/pons (0.46 nmol/g) > cortex (0.39 nmol/g). 5-5-Cys-Gly-DA
96
<c 
c
2u
3
U
10 A. S t r i a t u m
ai nA
4 -
X XX X X _ J
4015 201 0 25
T i m e /m in
<
C
c
2
3
0
T i m e /m in
<
C
c
2u
3
ü
10 B. M id b ra in
8
6
4
2
oo 5 1 0 15 20 25 35 4030
1 0 C . H i p p o c a m p u s
10 15
T im e /m in
20 25 30 35 40
Figure 4.4 15 min after icv administration of 44 nmol S-S-GIu-DA to rat. (A) striatum, (B)
midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method XTH. 
Injection volume = 5 pL. Insets in (A) and (E) show peaks of 5-S-Glu-D A and S-S- 
Cys-Gly-DA in details. (Continued on the next page)
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Figure 4.4 (Continue from the previous page)
15 min after icv administration of 44 nmol (20 pg) 5-S-Glu-DA to rat. (A) striatum, 
(B) midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method 
Xm. Injection volume = 5 pL. Insets in (A) and (E) show peaks of S-S-Glu-DA and 
5-5-Cys-Gly-DA in details.
disappeared from the medulla/pons 15 min after icv administration of 5-5-Glu-DA. 5-5- 
Cys-Gly-DA disappeared from striatum and midbrain 30 min after icv administration, and 
from hippocampus and cortex within 60 min after icv administration of 5-5-Glu-DA. The 
first step of hydrolysis of 5-5-Glu-DA is the conversion of 5-5-Glu-DA itself into 5-5-Cys- 
Gly-DA and this step seemed to be the rate limiting step. The concentration of 5-5-Cys- 
Gly-D A was just high enough to be detected under the current conditions. Once 5-5-Glu-
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Figure 4.5 Striatum of rats after icv administration of 44 nmol (20 ng) 5-S-Glu-DA. Each data point represents the mean ± SE of 3-4 rats.
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Figure 4.8 Cortex of rats after icv administration of 44 nmol (20 ng) 5-S-Glu-DA. Each data point represents the mean ± SE of 3-4 rats.
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Figure 4.9 Medulla/pons of rats aOer icv administration of 44 nmol (20 pg) 5-S'-Glu-DA. Each data point represents the mean ± SE of 3-4 rats.
DA is gone, 5-5-Cys-Gly-DA can no be longer detected.
As in the in vitro metabolism of 5-&GIu-DA, S-^-Cys-DA is also a major 
metabolite of the in vivo metabolism of 5-&Glu-DA The concentration of S-iî-Cys-DA 
reached a maximum level 15 min after icv administration of 5-J-Glu-DA in the order 
striatum (10.8 nmol/g) > midbrain (7.8 nmol/g) > cortex (3.9 nmol/g) > medulla/pons (7.0 
nmol/g); and 30 min after icv administration in the hippocampus (19.3 nmol/g). In the 
midbrain, only 5 min after icv administration, the concentration of 5-&Cys-DA was of 
98% of the maximum level (Figure 4.6). 15 min after icv administration of 5-5’-Glu-DA, 
the concentration of 5-5-Cys-DA reached 98% of its maximum in the hippocampus 
(Figure 4.7). However, at the end of the experiment, the relative level o f 5-5'-Cys-DA was 
the lowest in midbrain, with a concentration of only 7% of the maximum value. The 
midbrain, therefore, is the region having the highest turnover rate for 5-5-Cys-DA. The 
clearance of 5-5-Cys-DA in other brain areas is as follows (% of the maximum level 
remaining); medulla/pons (14%), hippocampus (16%), striatum (32%) and cortex (54%).
Another major metabolite detected in the in vivo metabolism of 5-5-Glu-DA was 
5-6'-NAc-Cys-DA, which did not appear in vitro. This may be attributed to the loss of 
activity of the enzyme — cysteinyl conjugate A'^acetyltransferase. It is still unclear why 
this particular enzyme loses its activity during the preparation of the brain homogenate, 
but among other things its substrate may be lost. Under in vivo conditions, 5-5-NAc-Cys- 
DA was formed in all brain areas studied. The patterns of the concentration change of 5-5- 
NAc-Cys-DA were quite different than that of 5-5-Cys-DA. Thus, the concentrations of 5- 
5-Cys-DA in all areas of the brain first reached their maximum levels and then decreased 
as the experiment continued. In contrast, the concentration of 5-5-NAc-Cys-DA first 
increased to a maximum level, then decreased to a minimum, and then increased again to a 
level even higher than the maximum at the end of the experiment in striatum (Figure 4.5).
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The concentration of 5-5-NAc-Cys-DA behaved in this manner only in the midbrain and 
hippocampus (Figure 4.6 and 4.7). In the cortex, the concentration of 5-5'-NAc-Cys-DA 
steadily increased without reaching a maximum at the end of the experiment (Figure 4.8). 
In medulla/pons, the concentration of 5-5-NAc-Cys-DA first increased to a maximum 
level then decreased to a minimum, and then slightly increased again at the end of the 
experiment (Figure 4.9). The concentration of 5-5-NAc-Cys-DA was found in brain areas 
in the order from the highest concentration to the lowest; midbrain (13.6 nmol/g, 30 min), 
hippocampus (12.6 nmol/g, 60 min), medulla/pons (6.03 nmol/g), striatum (5.91 nmol/g, 
120 min), and cortex (5.86 nmol/g, 120 min).
4.4.2 Icv administration of S'5-Cys-DA
44 nmol 5-iy-Cys-DA was icv administered into the left lateral ventricles through 
pre-installed cannulas as described in Chap. 3. 3 rats were used in each group that were 
sacrificed 15, 30, 60 and 120 min after icv administration of 5-&Cys-DA. Typical HPLC- 
EC chromatograms fi’om different brain areas 15 min after icv administration of 5-5’-Cys- 
DA are shown in Figure 4.10. The changes of 5-5-Cys-DA levels and its metabolite 5-5- 
NAc-Cys-DA in different brain areas are shown in Figure 4.11 to 4.15.
In the striatum the concentration of 5-5-Cys-DA steadily decreased fi'om the initial 
value of 9.92 nmol/g to 4.38 nmol/g, a 56% decrease within 2 h. Correspondingly, the 
concentration of 5-5-NAc-Cys-DA increased from 0.68 nmol/g to 2.49 nmol/g (Figure 
4.11).
In the midbrain the concentration of 5-5-Cys-DA also steadily decreased fi’om 8.67 
nmol/g to 1.92 nmol/g (78%) in 2 h (Figure 4.12).
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Figure 4.10 15 min after icv administration of 44 nmol S-S'-Cys-DA to rat. (A) striatum, (B)
midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method XIII. 
Injection volume = 5 pL. (Continued on the next page.)
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Figure 4 . 1 0  (Continued from previous page)
15 min after icv administration of 44 nmol 5-S’-Cys-DA to rat. (A) striatum, (B) 
midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method XUI. 
Injection volume = 5 pL.
In the hippocampus, the concentration of 5-5'-Cys-DA decreased from 10.6 nmol/g 
15 min after icv administration to 5.55 nmol/g after 30 min. The concentration of 5-5-Cys- 
DA then increased slightly and decreased again. The concentration of 5-5-NAc-Cys-DA 
was about linearly increased with respect to the incubation time (Figure 4.13).
The concentration of 5-5-Cys-DA in the cortex was first increased to a maximum 
of 4.27 nmol/g 30 min after icv administration of 5-5-Cys-DA and then decreased to
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Figure 4.11 Rat striatum after icv administration 44 nmol ( 12 (ig) 5-5'-Cys-DA. Each data point represents the mean ± SE of 3 rats.
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Figure 4.12 Rat midbrain aller icv administration of 44 nmol ( 12 ng) 5 ^Cys-DA. Each data point represents the mean ± SE of 3 rats.
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Figure 4.13 Rat hippocampus after icv administration of 44 nmol (12 pg) 5-S'-(rys-DA. Each data point represents the mean ± SE of 3 rats.
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Figure 4.14 Rat cortex after icv administration of 44 nmol ( 12 pg) 5-S'-Cys-DA. Each data point represents the mean ± SE of 3 rats.
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Figure 4.15 Rat medulla/pons after icv administration of 44 nmol (12 pg) 5-S-(Tys-DA. Each data point represents the mean ± SE of 3 rats.
1.98 nmol/g after 2 h. The concentration of 5-5-NAc-Cys-DA increased from barely 
nothing (0.12 nmol/g) 5 min after icv administration of 5-5-Cys-DA to 1.39 nmol/g after 2 
h (Figure 4.14).
The concentrations of S-^-Cys-DA and 5-5-N A c-Cys-D A  in medulla/pons 
increased to a maximum at 6.75 nmol/g and 2.92 nmol/g, respectively, 30 min after icv 
administration of 5-5-Cys-DA.
The highest concentrations of 5-5'-Cys-DA were found as 10.6 nmol/g in the 
hippocampus (15 min), 9.92 nmol/g in the striatum (15 min), 8.67 nmol/g in the midbrain 
(15 min), 6.75 nmol/g in the medulla/pons (30 min), and 4.27 nmol/g in the cortex (30 
min) respectively. The highest concentrations of 5-S'-NAc-Cys-DA were found as 4.67 
nmol/g in the midbrain (30 min), 3.42 nmol/g in the hippocampus (120 min), 2.92 nmol/g 
in the medulla/pons (30 min), 2.49 nmol/g in the striatum (120 min), and 1.39 nmol/g in 
the cortex (120 min), respectively.
The concentrations of 5-6"-Cys-DA in each brain area should be decreased after lev 
administration of 5-5-Cys-DA, while the concentrations of S-^-NAc-Cys-DA should be 
increased after icv administration. However, on certain occasions the concentration did 
not change in this way. Further statistical treatment (one-way ANOVA applied to two 
adjacent data points) showed no significant differences in those changes. Those abnormal 
changes can thus be attributed to the differences of individual rats.
4.4.3 Icv administration of 5-5-Cys-Gly-DA
5-&Cys-Gly-DA was dissolved in artificial CSF and the pH was adjusted to neutral 
(pH = 7.0 ± 0.5) as described in Chap. 3. 44 nmol S-j'-Cys-Gly-DA (24 pg 5-5'-Cys-Gly-
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DA»2TFA) was icv administered into the left lateral ventricle through pre-installed 
cannulas on rats as described previously. 5, 30 and 60 min after icv administration of the 
drug, rats were sacrificed. One rat was used for each time period. The HPLC-EC 
chromatograms of brain sample obtained 5 min after icv administration of 5-&Cys-Gly- 
DA are shown in Figure 4.16. Data are summarized in Table 4.2.
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Figure 4.16 5 min after icv administration of 44 nmol (24 ug) 5-5-Cys-Gly-DA to rat. (A) striatum, 
(B) midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method XIII. 
Injection volume = 5 pL.
(Continued on the next page)
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Figure 4.16 (Continued from previous page)
5 min after icv administration of 44 nmol (24 pg) S-S-Cys-Gly-DA to rat. (A) striatum, 
(B) midbrain, (C) hippocampus, (D) cortex and (E) medulla/pons. HPLC method XIII. 
Injection volume = 5 pL.
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Table 4.2 DA Conjugates (nmol/g) Detected after lev Administration of S-f-Cys-Gly-DA 
Time/min S-S-NAc-Cys-DA S-S-Cys-Gly-DA 5-S-Cys-DA S-S-Glu-DA
Striatum 5 0.00 0.11 0.80 0.00
30 4.11 0.00 14.88 0.00
60 4.08 0.00 3.15 0.00
Midbrain 5 7.00 1.55 28.30 4.03
30 3.50 0.00 2.79 0.00
60 11.30 0.00 1.25 0.00
Hippocampus 5 3.37 4.01 63.90 0.84
30 8.58 0.00 32.44 0.00
60 1.82 0.00 0.16 0.00
Cortex 5 0.58 0.26 6.34 0.04
30 0.93 0.00 5.61 0.00
60 0.95 0.00 0.67 0.00
Medulla/pons 5 0.67 0.19 1.88 0.00
30 1.78 0.00 0.85 0.00
60 12.36 0.00 5.75 0.00
As expected, 5-5-Cys-Gly-DA was metabolized to 5-&Cys-DA and 5-5’-NAc-Cys-DA 
through peptidase(s) and cysteinyl conjugate A-acetyltransferase. The highest 
concentration of 5-5-Cys-DA was found in the hippocampus (63.9 nmol/g), followed by 
midbrain (28.3 nmol/g), cortex (6.3 nmol/g), medulla/pons (1.88 nmol/g) and striatum (0.8 
nmol/g). 60 min after icv administration of S-iî-Cys-Gly-DA, the concentration of 5-S- 
NAc-Cys-DA was found highest in the medulla/pons (12.4 nmol/g), followed by midbrain 
(11.3 nmol/g), striatum (4.1 nmol/g), hippocampus (1.82 nmol/g) and cortex (0.9 nmol/g).
5-5-Glu-DA was detected shortly (5 min) after icv administration of 5-5'-Cys-Gly- 
DA in the midbrain, hippocampus and cortex and disappeared with 5-^-Cys-Gly-DA.
4.6 Discussion
The experimental results in this chapter demonstrate that 5-5'-Glu-DA and 2,5-bis-
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5-GIu-DA are hydrolyzed to their corresponding cysteinyl conjugates, 5-5-Cys-DA and
2.5-bis-5-Cys-DA, respectively, in rat brain homogenate at physiological pH (pH = 7.4). 
The hydrolysis of glutathionyl conjugates into cysteinyl conjugates involves the
removal of the y-glutamyl group from glutathionyl substituent by y-glutamyl 
transpeptidase, followed by the cleavage of glycinyl group from cysteinylglycinyl 
conjugates of DA by a dipeptidase. The cysteinyl conjugates of DA were A’-acetylized by 
cysteine conjugates A''-acetyltransferase to form #-acetylcysteinyl conjugates of DA. The 
process is illustrated by the hydrolysis of 5-5-Glu-DA in Scheme VI below.
Scheme VI
H O ' V  H O -V ^
O S 7-GT o  S
^  u j   ► ^  u j  + Glutamate
æ æ  H Y  ' ----------- H O O C -f lY
O S-S-Cy&Gly-DA
S'S-Glu-DA I
I Dipeptidase(s)
Cysteinyl conjugate 
Wacetyltransferase h o ' ^ t
jj S  ► s  + glycine
^3^ Y  y  AAacetylcysteinyl
O COOH conjugate |
AWeacetylase COOH
5^-NAc-Cy&OA S-S^&OA
The in vitro hydrolysis of 2,5-bis-5-Glu-DA had a more complicated process with 
several metabolites remaining unidentified. Possible metabolites during the hydrolysis of
2.5-bis-5-Glu-DA are sketched in Scheme VU, supposing that the first amino acid group 
to be removed is a glutamyl group. The unidentified chromatographic peaks might have 
structures among those in Scheme VII.
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Scheme VII
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The first step in the metabolism of glutathionyl conjugates of DA is to remove the 
glutamyl group catalyzed by y-GT, followed by the removal of a glycinyl moiety from the 
resulting cysteinylglycinyl conjugate by a dipeptidase
When 5-5'-Cys-Gly-DA was administered into rat brain for 5 min, 5-5-Glu-DA was 
observed in all brain areas, though the concentrations of 5-5-Glu-DA were below the 
quantitative range in some areas (i.e., striatum and cortex). This might be due to the 
activity of y-GT. y-GT is a membrane-bound protein that catalyzes the transfer of the y- 
glutamyl group of glutathione and glutathionyl conjugates and other y-glutamyl peptides 
to an acceptor molecule. The acceptor molecules may be an animo acids, dipeptides, 
glutathione itself and water‘d®. When 5-5-Cys-Gly-DA was administered into the rat brain 
the local concentration of 5-&Cys-Gly-DA is much higher than the concentration 
experienced during the hydrolysis of S-i'-Glu-DA. Therefore, 5-5-Cys-Gly-DA might act 
as an acceptor of glutamyl group. Finally, the cysteinyl conjugates of DA is V-acetylated 
by cysteinyl conjugates V-acetyltransferase.
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Other enzymes involved in the hydrolysis of glutathionyl conjugates are cysteinyl 
conjugate A^-acetyltransferase and iV-acetylcysteinyl conjugate deacetylase. However, the 
activities of these two enzymes were only observed in vivo in this study. 5-5-Glu-DA was 
cleared from all brain regions within 60 min. Correspondingly, the concentrations of 5-5- 
Cys-DA reached maximum within 15 min. 5-5-Cys-DA was then acetylated to give rise 5- 
5-NAc-Cys-DA. The maximum concentration of 5-5-NAc-Cys-DA occurred to be about 
15 to 30 min after that of 5-5-Cys-DA The dipeptidyl conjugate of DA, 5-5-Cys-Gly-DA 
was momentarily detected before 5-5-Glu-D A was cleared from the brain.
The hydrolysis 5-5-Glu-DA into 5-5-Cys-DA was confirmed experimentally the 
first time in this experiment. The only similar experiment carried out in rat brain was the 
hydrolysis of 5-Glu-a-methyldopamine^, which is a putative metabolite of 3, 4-(±)- 
(methylenedioxy)-amphetamine (MDA) and 3,4-(±)-(methylenedioxy)-methamphetamine 
(MDMA) that do not exit in brain.
The metabolism of glutathionyl conjugates of DA to 7V-acetylcysteinyl conjugates 
of DA is called the mercapturic acid pathway. This pathway usually occurs at locations 
with relatively high activities of y-GT, cysteinylglycine dipeptidase(s), and A'-acetyl 
transferases, such as the kidney. The normal function of this pathway is to form the water- 
soluble metabolites that can be excreted from the body and therefore to detoxify potential 
toxicants. Whether this is a detoxification process, however, depends on the properties of 
the metabolites thus formed. In the MDA and MDMA study, the final W-acetylcysteinyl 
conjugates were considered as the reason for the neurotoxic properties of MDA and 
MDMA. Instead of W-acetylation, cysteinyl conjugates of DA may form benzothiazines via 
the intramolecular cyclization of the cysteinyl conjugates. This is also believed to be a 
general detoxification process®®. However, in the case of DA, both the W-acetylcysteinyl 
conjugates and dihydrobenzothiazines are toxic when administered in mouse brain.
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Therefore, if the glutathionyl conjugate of DA is formed in brain under certain conditions, 
it might undergo the hydrolysis process described in this chapter. The further metabolism 
the cysteinyl conjugate of DA may form toxic metabolites and eventually contribute to the 
neurodegeneration.
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Conclusions
Dopaminergic neurons degenerate in their pigmented cell bodies in the SN of PD 
patients*®. The pigmentation occurs as a result of the autoxidation of cytoplasmic DA to 
DA-o-quinone which polymerizes to black neuromelanin**. The characteristic 
biochemical changes include; 1) a massive loss of GSH without a corresponding increase 
in GSSG (oxidized GSH)“’’*“  2) increased 5-S-Cys-DA/DA concentration ratio**, 3) 
increased y-GT activity"*, and 4) the depigmentation of the SN cells. A new hypothesis** 
based on these observations suggests that an elevated y-GT-mediated translocation of 
GSH or cysteine into the SN cell bodies is an early step in the pathogenesis of PD. In 
vitro study** suggests that cysteine would divert the neuromelanin pathway by scavenging 
DA-o-quinone to form soluble cysteinyl conjugates of DA causing the depigmentation of 
the SN cells and an increase of the 5-5-Cys-DA/DA concentration ratio. The subsequent 
autoxidation of cysteinyldopamines would lead to the toxic products which might lead to 
nigral cell death and PD.
The noradrenergic neurons degenerate in the cell bodies in the LC in PD patients. 
The noradrenergic neurons that project from LC to the cortex and hippocampus also 
degenerate in AD patients"®. The neurodegenerative processes occur in noradrenergic cell 
bodies in PD but in terminal regions in AD. There is a significant concentration of GSH 
in terminal regions of noradrenergic neurons. In vitro study®* shows that cysteine would 
divert the melanin pathway by scavenging NE-o-quinone to form soluble cysteinyl 
conjugates of NE, which are further oxidized to form DHBTs. Among them, DHBTl and 
DHBT2 are lethal when administered into the mouse brain**’*®.
121
Due to the facile oxidation of NE and DA under cytoplasmic autoxidation 
conditions, the o-quinones of NE and DA may be nucleophilically attacked by GSH to 
give glutathionyl conjugates, which are subsequently hydrolyzed to form cysteinyl 
conjugates. The cysteinyl conjugates of NE and DA are more easily be oxidized than NE 
and DA themselves in physiological conditions in vitro. Therefore, under the conditions 
where NE and DA are oxidized, the cysteinyl conjugates of NE and DA would also be 
oxidized and lead to the formation of a series of toxic products contributing to cell death.
This project studied the in vitro oxidation of NE in the presence of GSH at 
physiological pH. The oxidation conditions included electro-oxidation, autoxidation, 
hydroxyl radical-mediated oxidation, and superoxide anion radical-mediated oxidation. 2- 
5-Glu-NE and S-^-Glu-NE were formed under all these conditions. In addition, 2,5-bis-5- 
Glu-NE and 2,5,6-tris-5-Glu-NE were formed under electro-oxidation and hydroxyl 
radical-mediated oxidation conditions. All these products were purified and structurally 
identified.
The metabolisms of glutathionyl conjugates of NE and DA were studied under 
both in vitro and in vivo conditions. Glutathionyl conjugates of NE and DA were 
converted to cysteinyl conjugates in vitro in whole rat brain homogenates at physiological 
pH. Cysteinyl conjugates of NE and DA were metabolized to cysteinylglycinyl 
conjugate, cysteinyl conjugates and A’-acetylcysteinyl conjugates of NE and DA in vivo 
after icv administration of glutathionyl conjugates to rats. The formation of glutathionyl 
conjugates and the subsequent conversion of glutathionyl conjugates to cysteinyl 
conjugates and finally to A’-acetylcysteinyl conjugates is called mercapturic acid 
pathway*^*. It is considered as a detoxification process. However, recent study**® showed
122
that AT-acetylcysteinyl conjugates of DA were toxic when administered into mouse brain.
In summary, the autoxidation of NE and DA in noradrenergic and dopaminergic 
neurons might be diverted by the nucleophilic attack of GSH and/or cysteine to form 
glutathionyl and/or cysteinyl conjugates of NE and DA, respectively. If glutathionyl 
conjugates of NE and DA could be formed under certain abnormal conditions such as 
oxidative stress, they may be metabolized to form the corresponding cysteinyl 
conjugates. Further metabolism of the cysteinyl conjugates may form A-acetylcysteinyl 
conjugates through enzyme-mediated reactions and might form DHBTs through 
cytoplasmic autoxidation. These metabolites together might represent endotoxins that 
contribute to the degeneration of noradrenergic and dopaminergic neurons in AD and PD 
patients.
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Appendix A Synthesis and Cyclic Voltammetric Study of 5- 
.S-(iV-Acetylcysteinyl)norepinephrine (5-5'-NAc- 
Cys-NE) and 5-6^Cysteinylglycinylnorepine- 
phrine (S-S'-Cys-Gly-NE)
A.1 Synthesis of 5-kS-NAc-Cys-NE
5 mg NE'HCl (24 mmol) was dissolved in 25 mL of 0.1 M HCl. The resulting 
solution was electrolyzed at 1.0 V for 60 minutes. ME was converted into NE-o-quinone 
and the solution turned a dark brown in color. Upon addition of 20 mg ^acetylcysteine, 
the solution turned colorless. The reaction solution was injected directly into a 
preparative HPLC system. HPLC method IV was employed and 2-5-NAc-Cys-NE and 5- 
5'-NAc-Cys-NE eluted at retention times of 22.9 and 26.2 min, respectively, with a ratio 
of 2:5. 5-5'-NAc-Cys-NE was collected by repeating the same procedure several times 
and freeze-dried. The resulting solid was dissolved in a minimum amount of deionized 
water and was purified (desalting) by HPLC method VI. The purified eluent was 
collected and freeze-dried.
5-5'-NAc-Cys-NE was a white solid compound and in PBS (pH = 7.4, p = 1.0), it 
exhibited UV bands at Xma%,nm (log Smax/M’^cm'*): 256 
(3.77) and 292 (3.57) (Figure B.23 in Appendix B). FAB- 
MS (thioglycerol/glycerol matrix) gave m/e = 331.0935 
(MH^\ 14.6%, C13H19N2O6S; calculated m/e = ^C O O H
331.09638) (Figure B.24 in Appendix B). ‘H NMR (D2O) 5-S-NAc-Cys-NE
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gave 5: 6.84 (d, h e  = 2.4 Hz, IH, C(2)-H), 6.73 (d, h e  = 2.4 Hz, IH, C(6)-H), 4.69-4.65 
(m, IH, C(p)-H), 4.12-4.08 (m, IH, C(b)-H), 3.26-3.20 (m, IH, C(a)-H), 3.10-2.90 (m, 
3H, C(a)-H, C(a)-H2), 1.68 (s, 3H, C(c)-H3) (Figure B.21 and B.22 in Appendix B).
A.2 Cyclic voltammetry of S-^S-NAc-Cys-NE
A cyclic voltammogram (v = 100 mVs'*) of 5-5-NAc-Cys-NE at PBS (pH = 7.4, 
p = 1.0) exhibited two oxidation peaks 1. (E? = 126 mV) and Ha (Ep = 570 mV) on the 
initial anodic sweep. After scan reversal, reduction peak Ic (Ep = 94 mV) formed a 
reversible couple with oxidation peak !.. At more negative potentials, reduction peak Die 
(Ep = -  238 mV) formed a reversible couple with oxidation peak 111» (Ep = -  212 mV)
Scheme VIII
OH OH OH
HOyC)_% k,NH; Peak I,
HO V  O V
HgC'^fj^COOH HjC'^ 'l^ '^ COOH f| COOH
M-NAc-CysfJE 13 14
OH ^  OH
Ho V - HHO
q S -2tr-2e q S
II I Peak III, u 1
HjC'^fj^COOH ' HjO'^ f '^^ COOH
16 15
which appeared on the second anodic sweep (Figure 3.1 A). Peak I» corresponds to the 
oxidation of 5-5-NAc-Cys-NE to 5-5-NAc-Cys-NE o-quinone (13) during the initial
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Cvclic voltamograms of 0.5 mM A) S-S-NAc-Cys-NE and B) 5-5-Cys- 
GÏy-NE in PBS (pH = 7.4. n = l.O). Sweep rate = 100 mVs '.
Figure 1
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anodic scan (Scheme V), while peak L corresponds to the 13. Compound 13 deprotonates 
to compound 14, which undergoes intramolecular cyclization to form indoline 15. Further 
chemical oxidation of the indoline IS by 13 may yield aminochrome 16. The proximate 
products of 15/16 couple are responsible for the peak nypeak Hla (Scheme V). However, 
the oxidation reaction corresponding to peak Ha is unknown and remained to be further 
investigated^’'^’.
A 3 Synthesis of S-iÇ-Cys-Gly-NE
5 mg NE'HCl (24 mmol) was dissolved in 25 mL of 0.1 M HCl. The resulting 
solution was electrolyzed at 1.0 V for 60 minutes. ME was converted into NE-o-quinone 
and the solution turned dark brown in color. Upon addition of 22 mg L-cysteinylglycine 
(124 mmol), the solution turned to colorless. The reaction solution was injected into 
preparative HPLC system, using HPLC method V. 2-5-Cys-Gly-NE and 5-5-Cys-Gly-NE 
were eluted at retention times of 20.9 and 24.3 minutes, respectively, with a peak area 
ratio of 1:4. 5-5-Cys-Gly-NE was collected by repeating the same procedure several 
times and freeze-dried. The resulting solid was dissolved in a minimum amount of 
deionized water and was purified using HPLC method VI. The purified eluent was 
collected and fi’eeze-dried.
5-5-Cys-Gly-NE was a white solid and in PBS (pH = 7.4, p = 1.0), it exhibited 
UV bands at X^ax.nm (log Sma.\/M'*cm'*): 252 sh (3.49), 296 (3.26) and 316 sh (2.89) 
(Figure B.27 in Appendix B). FAB-MS (thioglycerol/glycerol matrix) gave m/e = 
346.1044 (MH^‘, 3.5%, C13H20N3O6S; calculated m/e = 346.1073) (Figure B.28 in
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Appendix B). ‘H NMR (D2O) gave Ô: 7.02 (d, Jz,6 = 
2.1 Hz, IH, C(2)-H), 6.90 (d, J2,e = 2.1 Hz, IH, C(6)- 
H), 4.83-4.81 (m, IH, C(p)-H), 4.19-4.16 (m, IH, 
C(b)-H), 3.60-3.54 (m, IH, C(a)-H), 3.44-3.31 (m, 
5H, C(a)-H, C(a)-H2, C(c)-H2> (Figure B.25 and 
B.26 in Appendix B).
2
hoY =  “
0
5-S*Cys-Gly*NE
C O O H
A.4 Cyclic voltammetry of 5-»y-Cys-Gly-NE
A cyclic voltammogram (v = 100 mVs'^) of 5-5-Cys-GIy-NE at PBS (pH = 7.4, p 
= 1.0) exhibited two oxidation peaks U (Ep = 90 mV) and 11» (Ep = 634 mV) on the initial 
anodic sweep. After scan reversal, reduction peak Ic (Ep = -  50 mV) formed a quasi- 
reversible couple with oxidation peak I,. There was no more peaks at more negative 
potentials during the scan reversal and second anodic sweep (Figure 3.1 B). Peak I, 
corresponds to the oxidation of 5-.9-Cys-Gly-NE to its o-quinone intermediate 17 
(Scheme VI) while peak Ic corresponds to the reduction 17 back to 5-5-Cys-Gly-NE. 
Compound 18 might have undergone intramolecular cyclization to o-quinone imine to 18, 
which ultimately converted into dihydrobenzenethiazine 20’®. The difference of the 
cyclic voltammetric behaviors between 5-5-NAc-Cys-NE and 5-5'-Cys-Gly-NE depends 
on the different ways of intramolecular cyclization. During the oxidation process, 5-5- 
Cys-Gly-NE utilizes the cysteine moiety for the intramolecular cylization. In contrast, 5- 
5-NAc-Cys-NE, with the amino group on the cysteine moiety protected by an acetyl 
group, utilizes the side chain on NE moiety for the intramolecular cyclization.
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Appendix B NMR ( H and COSY), UV Vis and MS Spectra
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Figure B.9 Low resolution FAB-MS spectrum of 5-&Glu-NE in thioglycerol/glycerol matrix.
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Figure B. 11 Correlated spectroscopy (COSY) contour o f 5-Y-Glu-NE in D2O.
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Figure B. 12 UV-visible spectrum o f 0 1 mM 2,5-bis-.V-Glu-NE in PBS (pH -  7.4, p -  1.0).
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Figure B. 13 Low resolution FAB-MS spectrum o f 2,5-bis-.V-Glu-NE in thioglycerol/glycero! matrix.
o  o  o  oo
z z
r
q
o
c
§
_3
o
cn
15
m
fS
(t.0
1
2
X
CD
2
&
(5
1 5 3
HOOC
HOOC.
'NH r  1 (PPM)
HOOC
HOOC
a J u L J U L
8
HO NH;
;
6
5
4
3
P
1 — ,
F 2 (PPM)
Figure B. 15 Correlated spectroscopy (COSY) contour of 2,5-bis-.V-Glu-NE in DiO.
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Figure B. 16 UV-visible spectrum of 0.1 mM 2,5,6-tris-.V-Glu-NE in PBS (pH = 7.4, p = 1.0).
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Figure B.I7 Low resolution FAB-MS spectrum of 2,5,6-tris-5-Glu-NE in thioglycerol/glycerol matrix.
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Figure B. 19 Correlated spectroscopy (COSY) contour o f 2,5,6-tris-.S-Glu-NE in DjO.
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Figure B 20 UV-visible spectrum ofO. I mM 5-.V-NAc-Cys-NE in PBS (pH = 7 4, p = 1.0).
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Figure B 21 Low resolution FAB-MS spectrum of 5-À'-NAc-Cys-NE in 3-nitrobenzyl alcohol matrix.
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Figure B 23 Correlated spectroscopy (COSY) contour o f 5-5-NAc-Cys-NE in D2O,
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Figure B 24 UV-visible spectrum o f 0 .1 mM 5-.S-Cys-Gly-NE in PBS (pH = 7.4, p = 1.0).
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Figure B 25 Low resolution FAB-MS spectrum of 5-iV-Cys-Gly-NE in 3-nitrobenzyl alcohol matrix.
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Figure B 26 ' H NMR of 5-.S’-Cys-Gly-NE in D2O.
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Figure B.27 Correlated spectroscopy (COSY) contour of 5-.V-Cys-Gly-NE in D^O.
Appendix C HPLC Methods
167
Table I HPLC Method I
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 0.0
20.00 30.0
35.00 100.0
45.00 100.0
46.00 0.0
49.95 7.000 0.0
50.00 0.000 0.0
Pump; Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 ntL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to
4.0 L deionized water, pH adjusted to 3.0 by TFA. 
Solvent B: 30.0 mL concentrated ammonium hydroxide added to
2.0 L methanol and 2.0 L deionized water, pH adjusted 
to 3.0 by TFA.
Table 2 HPLC Method H
Time/min Flow/mL/min %D
0.00 7.000 0.0
2.00 0.0
40.00 100.0
45.00 100.0
46.00 0.0
49.95 7.000 0.0
50.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent C: 4.0 L deionized water, pH adjusted to 3.0 by TFA. 
Solvent D: 2.0 L acetonitrile and 2.0 L deionized water, pH 
adjusted to 3.0 by TFA.
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Table 3 HPLC Method m
Isocratic at a constant flow rate o f 0.6 mL/min
Pump; Bio-Rad Model 1300
Detector: BAS LC-4C electrochemical detector, full range set to 10 nA
Column: BAS, Phase-II ODS, 3 pm, 100 x 3.2 mm
Injector: Rhoedyne model 7125 injector with 5 pL loop
Solvent: Add 3.4 mL diethylamine, 76 mg NajEDTA (anhydrite), 84 g
citric acid, and 464 mg sodium octyl sulfate to 3630 ml 
deionized water, filter, add 370 mL acetonitrile, and degas. 
pH =  2.34.
Table 4 HPLC Method IV
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 0.0
25.00 45.0
25.50 100.0
45.00 100.0
45.01 0.0
54.95 7.000 0.0
55.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to
4.0 L deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to 3.0 by 
TFA.
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Tables HPLC Method V
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 0.0
25.00 45.0
25.50 100.0
40.00 100.0
40.01 0.0
49.95 7.000 0.0
50.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to
4.0 L deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to  3.0 by 
TFA.
Table 6 HPLC Method VI
Time/min Flow/mL/min %F
0.00 7.000 0.0
5.00 0.0
45.00 40.0
45.01 0.0
54.90 7.000 0.0
55.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent E: Deionized water.
Solvent F: Acetonitrile.
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Table? HPLC Method VH
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 1.0
25.00 5.0
36.00 100.0
46.00 100.0
47.00 0.0
54.90 7.000 0.0
55.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to
4.0 L deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to 3.0 by 
TFA.
Tables HPLC Method V m
Isocratic at a constant flow rate of 0.6 mL/min 
Pump: Bio-Rad Model 1300
Detector: BAS LC-4C electrochemical detector, fiill range set to 10 nA
Column: BAS, Phase-U ODS, 3 pm, 100 x 3.2 mm
Injector: Rhoedyne model 7125 injector with 5 pL loop
Solvent: Add 3.4 mL diethylamine, 88 mg Na2EDTA»2H20, 20.8 g
citric acid, and 436 mg sodium octyl sulfate to 3800 mL 
deionized water, filter, add 120 mL methanol, and degas. 
Final pH is adjusted to 2.30 by concentrated HCl.
1 7 1
Table 9 HPLC Method IX
Isocratic at a constant flow rate o f  0.9 mL/min 
Pump; Bio-Rad Model 1300
Detector: BAS LC-4C electrochemical detector, full range set to 10 nA
Column: BAS, Phase-II ODS, 3 pm, 100 ^ 3.2 mm
Injector: Rhoedyne model 7125 injector with 5 pL loop
Solvent: Add 3.4 mL diethylamine, 88 mg Na2EDTA»2H20, 20.8 g
citric acid, and 436 mg sodium octyl sulfate to 3800 mL 
deionized water, filter, add 120 mL methanol, and degas. 
Final pH is adjusted to 2.30 by concentrated HCl.
Table 10 HPLC Method X
Time/min Flow/mL/min %B
0.00 0.000 0.0
0.05 7.000 0.0
2.00 0.0
20.00 30.0
35.00 100.0
45.00 100.0
46.00 0.0
49.95 7.000 0.0
50.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 n i  concentrated ammonium hydroxide added to 4.0 L 
deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to 3.0 by 
TFA
1 7 2
Table 11 HPLC Method XI
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 0.0
25.00 28.0
25.50 100.0
35.00 100.0
35.01 0.0
44.95 7.000 0.0
45.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to 4.0 L 
deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to 3.0 by 
TFA.
Table 12 HPLC Method XH
Time/min Flow/mL/min %B
0.00 7.000 0.0
2.00 0.0
25.00 45.0
25.50 100.0
40.00 100.0
40.01 0.0
49.95 7.000 0.0
50.00 0.000 0.0
Pump: Two Gilson model 302 pumps
Detector: Gilson model 112 UV detector set at 254 nm
Column: J. T. Baker, Bakerbond C-18, 10 pm, 22.5 x 250 mm
Injector: Rheodyne model 7125 with 10.0 mL loop.
Solvent A: 30.0 mL concentrated ammonium hydroxide added to
4.0 L deionized water, pH adjusted to 3.0 by TFA.
Solvent B: 30.0 mL concentrated ammonium hydroxide added to 2.0 L 
methanol and 2.0 L deionized water, pH adjusted to 3.0 by 
TFA.
1 7 3
Table 13 HPLC Method X m
Isocratic at a constant flow rate of 0.6 mL/min
Pump: Bio-Rad Model 1300
Detector: BAS LC-4C electrochemical detector, full range set to 10 nA
Column: BAS, Phase-II ODS, 3 pm, 100 x 3.2 mm
Injector: Rhoedyne model 7125 injector with 5 pL loop
Solvent: Add 3.4 mL diethylamine, 83 mg Na2EDTA«H20, 84 g citric
acid, and 436 mg sodium octyl sulfate to 3800 ml deionized 
water, filter, add 250 mL acetonitrile, and degas. pH is 
adjusted to 2.37 by concentrated HCl and/or NaOH.
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